<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease - Farne, HA - 2015 | Cochrane Library</title> <meta content="Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease - Farne, HA - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008989.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease - Farne, HA - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008989.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008989.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Long‐acting beta&lt;sub&gt;2&lt;/sub&gt;‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta&lt;sub&gt;2&lt;/sub&gt;‐agonist alone for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Hugo A Farne" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="hugo.farne@gmail.com" name="citation_author_email"/> <meta content="Christopher J Cates" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD008989.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/10/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008989.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008989.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008989.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; Albuterol [analogs &amp; derivatives, therapeutic use]; Bronchodilator Agents [*therapeutic use]; Ethanolamines [therapeutic use]; Formoterol Fumarate [therapeutic use]; Indans [therapeutic use]; Pulmonary Disease, Chronic Obstructive [*drug therapy]; Quality of Life; Quinolones [therapeutic use]; Randomized Controlled Trials as Topic; Salmeterol Xinafoate [therapeutic use]; Scopolamine Derivatives [therapeutic use]; Tiotropium Bromide [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008989.pub3&amp;doi=10.1002/14651858.CD008989.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008989\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008989\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008989.pub3",title:"Long\\u2010acting beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonist in addition to tiotropium versus either tiotropium or long\\u2010acting beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonist alone for chronic obstructive pulmonary disease",firstPublishedDate:"Oct 22, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008989.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008989.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008989.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008989.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008989.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008989.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008989.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008989.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008989.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008989.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4425 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008989.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-sec-0023"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-sec-0024"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/appendices#CD008989-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/table_n/CD008989StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/table_n/CD008989StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Long‐acting beta<sub>2</sub>‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta<sub>2</sub>‐agonist alone for chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/information#CD008989-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hugo A Farne</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008989.pub3/information#CD008989-cr-0003">Christopher J Cates</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/information/en#CD008989-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 October 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008989.pub3">https://doi.org/10.1002/14651858.CD008989.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008989-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008989-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008989-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008989-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008989-abs-0001" lang="en"> <section id="CD008989-sec-0001"> <h3 class="title" id="CD008989-sec-0001">Background</h3> <p>Long‐acting bronchodilators, comprising long‐acting beta<sub>2</sub>‐agonists (LABA) and long‐acting anti‐muscarinic agents (LAMA, principally tiotropium), are commonly used for managing persistent symptoms of chronic obstructive pulmonary disease (COPD). Combining these treatments, which have different mechanisms of action, may be more effective than the individual components. However, the benefits and risks of combining tiotropium and LABAs for the treatment of COPD are unclear. </p> </section> <section id="CD008989-sec-0002"> <h3 class="title" id="CD008989-sec-0002">Objectives</h3> <p>To compare the relative effects on markers of quality of life, exacerbations, symptoms, lung function and serious adverse events in people with COPD randomised to LABA plus tiotropium versus tiotropium alone; or LABA plus tiotropium versus LABA alone. </p> </section> <section id="CD008989-sec-0003"> <h3 class="title" id="CD008989-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register of trials and ClinicalTrials.gov up to July 2015. </p> </section> <section id="CD008989-sec-0004"> <h3 class="title" id="CD008989-sec-0004">Selection criteria</h3> <p>We included parallel‐group, randomised controlled trials of three months or longer comparing treatment with tiotropium in addition to LABA against tiotropium or LABA alone for people with COPD. </p> </section> <section id="CD008989-sec-0005"> <h3 class="title" id="CD008989-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion and then extracted data on trial quality and the outcome results. We contacted study authors for additional information. We collected information on adverse effects from the trials. </p> </section> <section id="CD008989-sec-0006"> <h3 class="title" id="CD008989-sec-0006">Main results</h3> <p>This review included 10 trials on 10,894 participants, mostly recruiting participants with moderate or severe COPD. All of the trials compared tiotropium in addition to LABA to tiotropium alone, and four trials additionally compared LAMA plus LABA with LABA alone. Four studies used the LABA olodaterol, three used indacaterol, two used formoterol, and one used salmeterol. </p> <p>Compared to tiotropium alone, treatment with tiotropium plus LABA resulted in a slightly larger improvement in mean health‐related quality of life (St George's Respiratory Questionnaire (SGRQ) (mean difference (MD) ‐1.34, 95% confidence interval (CI) ‐1.87 to ‐0.80; 6709 participants; 5 studies). The MD was smaller than the four units that is considered clinically important, but a responder analysis indicated that 7% more participants receiving tiotropium plus LABA had a noticeable benefit (greater than four units) from treatment in comparison to tiotropium alone. In the control arm in one study, which was tiotropium alone, the SGRQ improved by falling 4.5 units from baseline and with tiotropium plus LABA the improvement was a fall of a further 1.3 units (on average). Most of the data came from studies using olodaterol. High withdrawal rates in the trials increased the uncertainty in this result, and the GRADE assessment for this outcome was therefore moderate. There were no significant differences in the other primary outcomes (hospital admission or mortality). </p> <p>The secondary outcome of pre‐bronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) showed a small mean increase with the addition of LABA over the control arm (MD 0.06, 95% CI 0.05 to 0.07; 9573 participants; 10 studies), which showed a change from baseline ranging from 0.03 L to 0.13 L with tiotropium alone. None of the other secondary outcomes (exacerbations, symptom scores, serious adverse events, and withdrawals) showed any statistically significant differences between the groups. There was moderate heterogeneity for both exacerbations and withdrawals. </p> <p>This review included data on four LABAs: two administered twice daily (salmeterol, formoterol) and two once daily (indacaterol, olodaterol). The results were largely from studies of olodaterol and there was insufficient information to assess whether the other LABAs were equivalent to olodaterol or each other. </p> <p>Comparing LABA plus tiotropium treatment with LABA alone, there was a small but significant improvement in SGRQ (MD ‐1.25, 95% CI ‐2.14 to ‐0.37; 3378 participants; 4 studies). The data came mostly from studies using olodaterol and, although the difference was smaller than four units, this still represented an increase of 10 people with a clinically important improvement for 100 treated. There was also an improvement in FEV<sub>1</sub> (MD 0.07, 95% CI 0.06 to 0.09; 3513 participants; 4 studies), and in addition an improvement in exacerbation rates (odds ratio (OR) 0.80, 95% CI 0.69 to 0.93; 3514 participants; 3 studies). </p> </section> <section id="CD008989-sec-0007"> <h3 class="title" id="CD008989-sec-0007">Authors' conclusions</h3> <p>The results from this review indicated a small mean improvement in health‐related quality of life and FEV<sub>1</sub> for participants on a combination of tiotropium and LABA compared to either agent alone, and this translated into a small increase in the number of responders on combination treatment. In addition, adding tiotropium to LABA reduced exacerbations, although adding LABA to tiotropium did not. Hospital admission and mortality were not altered by adding LABA to tiotropium, although there may not be enough data. While it is possible that this is affected by higher attrition in the tiotropium group, one would expect that participants withdrawn from the study would have had less favourable outcomes; this means that the expected direction of attrition bias would be to reduce the estimated benefit of the combination treatment. The results were largely from studies of olodaterol and there was insufficient information to assess whether the other LABAs were equivalent to olodaterol or each other. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008989-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008989-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008989-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008989-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008989-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008989-abs-0003" lang="en"> <h3>For people with COPD, is it better to take a combination of tiotropium and long‐acting beta2‐agonists than either inhaler alone? </h3> <p><b>What is COPD?</b> </p> <p>Chronic obstructive pulmonary disease (COPD) is a lung disease that includes the conditions chronic bronchitis and emphysema. The symptoms include breathlessness and a chronic cough. COPD is an irreversible disease that is usually brought on by airway irritants, such as smoking or inhaled dust. </p> <p><b>What are tiotropium and long‐acting beta<sub>2</sub>‐agonists?</b> </p> <p>Tiotropium and long‐acting beta<sub>2</sub>‐agonists (LABAs) are two types of inhaled medicines that help widen the airways (bronchodilators) for up to 12 to 24 hours. These bronchodilators are commonly used to manage persistent symptoms of COPD. They can be used in combination or on their own. </p> <p><b>Why is the question important?</b> </p> <p>These bronchodilators work in different ways and therefore might be more beneficial if used together. The purpose of this review was to determine the benefits and risks of using a combination of both types of bronchodilator compared to the individual bronchodilators. </p> <p><b>How did we answer the question?</b> </p> <p>Two people looked for published and unpublished research in several databases and websites to find relevant studies comparing tiotropium plus LABA with either (tiotropium or a LABA) on its own in adults with COPD. We analysed the results available up to July 2015 in this systematic review. </p> <p><b>What did we find?</b> </p> <p>We found 10 studies involving 10,894 participants comparing the long‐term effectiveness and side effects of combining tiotropium with a LABA. The combination of tiotropium plus LABA resulted, on average, in a slightly better quality of life and lung function for the participants compared to using only either tiotropium or a LABA alone, but did not show a difference in hospital admissions or death. The combination treatment also reduced the risk of episodes of acutely worse symptoms ('exacerbations'), compared to a LABA alone but not tiotropium. There were not enough data to determine the risks and benefits of the different types of LABA. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008989-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008989-sec-0093">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008989-sec-0151">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008989-sec-0093"></div> <h3 class="title" id="CD008989-sec-0094">Implications for practice</h3> <section id="CD008989-sec-0094"> <p>The results from this review indicate a small mean improvement in health‐related quality of life and forced expiratory volume in one second (FEV<sub>1</sub>) for people taking a combination of tiotropium plus LABA compared to tiotropium alone, but it is not clear how clinically important this mean difference may be. This review now includes data on four long‐acting beta<sub>2</sub>‐agonist (LABAs): two administered twice daily (salmeterol, formoterol) and two administered once daily (indacaterol, olodaterol); the results were comparable for each agent. Hospital admission and mortality were not altered by adding LABA to tiotropium. There were not enough data to determine the relative efficacy and safety of tiotropium plus LABA compared to LABA alone. There were insufficient data to make comparisons between the different LABA when used in addition to tiotropium. </p> </section> <h3 class="title" id="CD008989-sec-0095">Implications for research</h3> <section id="CD008989-sec-0095"> <p>Additional long‐term (12 months or longer) larger studies are needed to clarify the risks and benefits of tiotropium plus LABA treatment compared to either drug alone. If the number of participants is large enough, this will enable analysis to assess the suitability of this combination of therapies for people with different severities of COPD. For quality of life measurements in future studies, it may be beneficial to use both mean changes with 95% confidence intervals and responders analysis. However, the responders analysis would preferably include both the number of people who have a clinically meaningful improvement as well as the number of people who have a clinically meaningful worsening. Presenting just one side of the data distribution, as in the percentage of people with a clinically meaningful improvement, is becoming more common but is of limited value. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008989-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008989-sec-0015"></div> <div class="table" id="CD008989-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Long‐acting beta2‐agonist plus tiotropium versus tiotropium alone</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus tiotropium alone for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> LABA + tiotropium<br/> <b>Comparison:</b> tiotropium </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tiotropium</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LABA + tiotropium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in quality of life<br/> assessed with: SGRQ<br/> Scale from 0 to 100 (lower score is better) </p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life at 6 months was <b>‐5.7 units</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>1.34 units lower</b> (1.87 lower to 0.8 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6709<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Better quality of life on combination treatment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life SGRQ responder analysis at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 100</b> <br/> (52 to 57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.32<br/> (1.19 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5978<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="./full#CD008989-fig-0001">Figure 1</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (all cause)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> <br/> (12 to 16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.01<br/> (0.86 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4856<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (exacerbation)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> <br/> (5 to 8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.02<br/> (0.80 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4856<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (all cause)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (7 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.24<br/> (0.81 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9633<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in trough FEV<sub>1</sub> (L) </p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in trough FEV<sub>1</sub> at 6 months was <b>0.06 L</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in trough FEV<sub>1</sub> in the intervention group was <b>0.06 L more</b> (0.05 more to 0.07 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9573<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonist; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SGRQ:</b> St George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> More drop‐outs with tiotropium alone </p> <p><sup>2</sup> Width of 95% CI limits our confidence in this outcome </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD008989-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="On tiotropium/olodaterol combination, at six months there were 55 SGRQ (St George's Respiratory Questionnaire) responders out of 100 (95% confidence interval 52 to 57) compared to 48 out of 100 on tiotropium alone." data-id="CD008989-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>On tiotropium/olodaterol combination, at six months there were 55 SGRQ (St George's Respiratory Questionnaire) responders out of 100 (95% confidence interval 52 to 57) compared to 48 out of 100 on tiotropium alone. </p> </div> </div> </div> <div class="table" id="CD008989-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Long‐acting beta2‐agonist plus tiotropium versus long‐acting beta2‐agonist alone</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus long‐acting beta<sub>2</sub>‐agonist alone for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> addition to tiotropium versus either tiotropium or long‐acting beta<sub>2</sub>‐agonist alone for chronic obstructive pulmonary disease<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> LABA plus tiotropium<br/> <b>Comparison:</b> LABA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LABA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LABA plus tiotropium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in quality of life<br/> assessed with: SGRQ<br/> Scale from 0 to 100 (lower score is better) </p> <p>Follow‐up: range 312 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life at 6 months was <b>‐5.7 units</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>1.25 units lower</b> (2.14 lower to 0.37 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3378<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Better quality of life on combination treatment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life SGRQ responder analysis at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 100</b> <br/> (51 to 59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.53<br/> (1.31 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2923<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="./full#CD008989-fig-0002">Figure 2</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (all cause)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> <br/> (11 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.93<br/> (0.76 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3514<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (exacerbation)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> <br/> (4 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.90<br/> (0.66 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3514<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (all cause)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (7 to 24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.15<br/> (0.62 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3514<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in trough FEV<sub>1</sub> (L) </p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in trough FEV<sub>1</sub> at 6 months was <b>0.05 L</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean trough FEV<sub>1</sub> in the intervention group was <b>0.07 L more</b> (0.06 more to 0.09 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3513<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonist; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SGRQ:</b> St George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> More drop‐outs on LABA alone </p> <p><sup>2</sup> Width of 95% CI limits our confidence in this outcome </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD008989-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="With tiotropium/olodaterol combination there were 55 SGRQ (St George's Respiratory Questionnaire) responders out of 100 (95% confidence interval 51 to 59) compared to 45 out of 100 with olodaterol alone." data-id="CD008989-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>With tiotropium/olodaterol combination there were 55 SGRQ (St George's Respiratory Questionnaire) responders out of 100 (95% confidence interval 51 to 59) compared to 45 out of 100 with olodaterol alone. </p> </div> </div> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008989-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008989-sec-0016">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008989-sec-0126">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD008989-sec-0016"></div> <section id="CD008989-sec-0017"> <h3 class="title" id="CD008989-sec-0017">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterised by chronic and progressive breathlessness, cough, sputum production, and airflow obstruction, which leads to restricted activity and poor quality of life (<a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>). According to the World Health Organization (WHO), COPD will become the third leading cause of death worldwide by 2030, with the treatment and management costs presenting a significant public health burden (<a href="./references#CD008989-bbs2-0127" title="World Health Organization. Chronic respiratory diseases: chronic obstructive pulmonary disease (COPD). www.who.int/respiratory/copd/en/ (accessed 10 March 2015). ">WHO</a>). In the UK, the annual cost of COPD to the National Health Service (NHS) is estimated to be GBP1.3 million per 100,000 people (<a href="./references#CD008989-bbs2-0115" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease. Costing report. Implementing NICE guidance. www.nice.org.uk/guidance/cg101/resources/cg101‐chronic‐obstructive‐pulmonary‐disease‐update‐costing‐report2 (accessed 9 July 2015). ">NICE 2011</a>). Furthermore, because of the slow onset and the under‐recognition of the disease, it is heavily under‐diagnosed (<a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>). COPD comprises a combination of bronchitis and emphysema and involves chronic inflammation and structural changes in the lung. Cigarette smoking is the most important risk factor, however biomass fuels (particularly in the developing world), air pollution, occupational dust, and chemicals are also recognised risk factors. COPD is a progressive disease leading to decreased lung function over time, even with the best available care. There is currently no cure for COPD, though it is both a preventable and treatable disease. As yet, apart from smoking cessation and non‐pharmacological treatments such as long‐term oxygen therapy in people with hypoxia, no intervention has been shown to reduce mortality (<a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>). Management of the disease is multi‐faceted and includes interventions for smoking cessation (<a href="./references#CD008989-bbs2-0124" title="van derMeerRM , WagenaE , OsteloRWJG , JacobsAJE , vanSchayckO . Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2001, Issue 1. [DOI: 10.1002/14651858.CD002999] ">van der Meer 2001</a>), pharmacological treatments (<a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>), education (<a href="./references#CD008989-bbs2-0129" title="ZwerinkM , Brusse‐KeizerM , van derValkPD , ZielhuisGA , MonninkhofEM , van derPalenJ , et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD002990.pub3; CD002990] ">Zwerink 2014</a>), and pulmonary rehabilitation (<a href="./references#CD008989-bbs2-0111" title="McCarthyB , CaseyD , DevaneD , MurphyK , MurphyE , LacasseY . Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003793.pub3] ">McCarthy 2015</a>). Pharmacological therapy is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline and even improving lung function, or preventing and treating exacerbations. COPD exacerbations impair people's quality of life (<a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>). Furthermore, a large part of the economic burden of COPD is attributed to the cost of managing exacerbations, particularly those resulting in use of acute care services or hospitalisations (<a href="./references#CD008989-bbs2-0103" title="HutchinsonA , BrandC , IrvingL , RobertsC , ThompsonP , CampbellD . Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medicine Journal2010;40(5):364‐71. ">Hutchinson 2010</a>). In the UK, one in eight emergency admissions to hospital is for COPD, which makes it the second largest cause of emergency admissions and one of the most costly conditions treated by the NHS (<a href="./references#CD008989-bbs2-0115" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease. Costing report. Implementing NICE guidance. www.nice.org.uk/guidance/cg101/resources/cg101‐chronic‐obstructive‐pulmonary‐disease‐update‐costing‐report2 (accessed 9 July 2015). ">NICE 2011</a>). Appropriate pharmacological management of the disease is therefore important to try to reduce and prevent exacerbations. </p> </section> <section id="CD008989-sec-0018"> <h3 class="title" id="CD008989-sec-0018">Description of the intervention</h3> <p>Pharmacological management of COPD tends to begin with one treatment and additional therapies are introduced, as necessary, to control symptoms (<a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>). The first step is often a short‐acting bronchodilator for control of breathlessness when needed, either a short‐acting beta<sub>2</sub>‐agonist (SABA) or the short‐acting anti‐muscarinic agent ipratropium. For persistent or worsening breathlessness associated with lung function decline, long‐acting bronchodilators may be introduced (<a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>). Long‐acting bronchodilators include twice‐daily long‐acting beta<sub>2</sub>‐agonists (LABA), such as salmeterol and formoterol; newer once‐daily LABAs, such as indacaterol and olodaterol; and long‐acting anti‐muscarinic (LAMA) agents, such as tiotropium, aclidinium, and glycopyrronium. Regular treatment with the LAMA tiotropium is more effective and safer than treatment with short‐acting ipratropium (<a href="./references#CD008989-bbs2-0099" title="CheyneL , Irvin‐SellersMJ , WhiteJ . Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 9. [DOI: 10.1002/14651858.CD009552.pub2] ">Cheyne 2013</a>). For symptomatic people with severe or very severe COPD (forced expiratory volume in one second (FEV<sub>1</sub>) less than 50% predicted) and repeated exacerbations, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends the addition of inhaled corticosteroids (ICS) to bronchodilator treatment (<a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>). </p> <p>This review focuses on tiotropium, as the longest established LAMA. Aclidinium is the subject of a separate Cochrane review (<a href="./references#CD008989-bbs2-0114" title="NiH , SoeZ , MoeS . Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD010509.pub2] ">Ni 2014</a>), and a protocol has been written for an ongoing Cochrane review of glycopyrronium (<a href="./references#CD008989-bbs2-0094" title="BurkeJP , EastmentJG , BowmanRV , FongKM , YangIA . Glycopyrronium bromide for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010798] ">Burke 2013</a>). </p> </section> <section id="CD008989-sec-0019"> <h3 class="title" id="CD008989-sec-0019">How the intervention might work</h3> <section id="CD008989-sec-0020"> <h4 class="title">Tiotropium</h4> <p>Tiotropium is an anti‐muscarinic agent that blocks the action of the neurotransmitter acetylcholine. It has an antagonistic effect on muscarinic acetylcholine receptors. Tiotropium has similar affinity for the five different subtypes of muscarinic receptors (M1 to M5), however airway smooth muscle expresses only the M2 and M3 subtypes (<a href="./references#CD008989-bbs2-0116" title="ProskocilBJ , FryerAD . Beta2‐agonist and anticholinergic drugs in the treatment of lung disease. Proceedings of the American Thoracic Society2005;2(4):305‐10. ">Proskocil 2005</a>). Activation of the M3 receptor stimulates a number of intracellular signalling cascades leading to changes in intracellular Ca<sup>2+</sup> homeostasis and contraction. Tiotropium dissociates slowly from M3 receptors giving a bronchodilator effect lasting over 24 hours, but dissociates rapidly from M2 receptors, which appear to be feedback inhibitory receptors (<a href="./references#CD008989-bbs2-0090" title="BarrRG , BourbeauJ , Camargo CarlosA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>). </p> <p>Tiotropium has gained widespread acceptance as a once‐daily maintenance therapy in stable COPD for its effects on symptoms and exacerbations (<a href="./references#CD008989-bbs2-0090" title="BarrRG , BourbeauJ , Camargo CarlosA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>; <a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>). In an early Cochrane review (<a href="./references#CD008989-bbs2-0090" title="BarrRG , BourbeauJ , Camargo CarlosA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>), tiotropium was shown to reduce the primary endpoint of people with COPD exacerbations compared to placebo (odds ratio (OR) 0.75, 95% CI 0.66 to 0.85). In the updated version of the review (<a href="./references#CD008989-bbs2-0107" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3] ">Karner 2014</a>), tiotropium was also associated with a significant benefit over placebo in breathlessness, quality of life, and a reduction in participants with exacerbations that required hospitalisation. Similar effects on symptoms and exacerbations were confirmed in a more recent, large randomised controlled trial (RCT) of almost 6000 participants who were followed for over four years (<a href="./references#CD008989-bbs2-0122" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal Medicine2008;359(15):1543‐54. ">Tashkin 2008a</a>). However, there was no significant effect of tiotropium on lung function decline in this longer study. Anticholinergic adverse effects that may occur with tiotropium include dry mouth, constipation, and tachycardia (<a href="./references#CD008989-bbs2-0122" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal Medicine2008;359(15):1543‐54. ">Tashkin 2008a</a>). There has been concern expressed about cardiovascular adverse events (AE) with tiotropium (<a href="./references#CD008989-bbs2-0120" title="SinghS . Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD. Evidence Based Medicine2009;14(2):42‐3. ">Singh 2009</a>), but this was not shown in a meta‐analysis including the UPLIFT (Understanding Potential Long‐term Impacts on Function with Tiotropium) study (<a href="./references#CD008989-bbs2-0098" title="CelliB , DecramerM , LeimerI , VogelU , KestenS , TashkinDP . Cardiovascular safety of tiotropium in patients with COPD. Chest2010; Vol. 137, issue 1:20‐30. [1931‐3543: (Electronic)] ">Celli 2010</a>). The results of one large head‐to‐head study comparing the dry powder and the soft mist inhaler for tiotropium have now been reported (<a href="./references#CD008989-bbs2-0128" title="WiseRA , AnzuetoA , CottonD , DahlR , DevinsT , DisseB , et al. Tiotropium Respimat inhaler and the risk of death in COPD. New England Journal of Medicine2013;369(16):1491‐501. ">Wise 2013</a>), and have not confirmed any important difference in mortality between the soft mist and dry powder inhalers. The study included people with a history of cardiac disease and stable heart failure, but people were not included in this study if they had a recent myocardial infarction, serious arrhythmia, cancer therapy, or drug and alcohol abuse. </p> </section> <section id="CD008989-sec-0021"> <h4 class="title">Long‐acting beta<sub>2</sub>‐agonists </h4> <p>Inhaled beta<sub>2</sub>‐agonists activate beta<sub>2</sub>‐receptors in the smooth muscle of the airway leading to a cascade of reactions that result in bronchodilation. Beta<sub>2</sub>‐agonists may also act through other mechanisms such as respiratory muscle function or mucociliary clearance because people have shown improvements in symptoms while showing no improvement in lung function tests. Beta<sub>2</sub>‐agonists are particularly useful bronchodilators because they reverse bronchoconstriction regardless of the initial cause. The commonly used twice‐daily LABAs, salmeterol and formoterol, and the once‐daily LABA, indacaterol, all have a higher selectivity for beta<sub>2</sub>‐receptors than beta<sub>1</sub>‐receptors (<a href="./references#CD008989-bbs2-0112" title="MoenMD . Indacaterol: in chronic obstructive pulmonary disease. Drugs2010;70(17):2269‐80. [0012‐6667: (Print)] ">Moen 2010</a>; <a href="./references#CD008989-bbs2-0125" title="WallukatG . The beta‐adrenergic receptors. Herz2002;27(7):683‐90. ">Wallukat 2002</a>). Beta<sub>2</sub>‐receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta<sub>1</sub>‐receptors are the predominant receptors in the heart, although 10% to 50% of the total beta‐receptors in the heart are comprised of beta<sub>2</sub>‐receptors. The presence of beta<sub>2</sub>‐receptors in the heart raises the possibility that even highly selective beta<sub>2</sub>‐agonists may have cardiac effects. The duration of action for salmeterol and formoterol is approximately 12 hours, and they are therefore usually taken twice daily. Indacaterol and olodaterol have a duration of action of 24 hours and can therefore be taken once daily. The mechanism for activating beta<sub>2</sub>‐receptors differs between these LABAs. Formoterol is taken up into a membrane depot from where it gradually leaks out to interact with the receptor, while salmeterol binds near the receptor, allowing it to remain at the receptor site continually binding and releasing (<a href="./references#CD008989-bbs2-0104" title="JohnsonM . The beta‐adrenoceptor. American Journal of Respiratory and Critical Care Medicine1998;158(5 Pt 3):S146‐53. ">Johnson 1998</a>). Indacaterol has a higher affinity to lipid domains within the membrane than salmeterol, which may potentially explain its prolonged duration of action (<a href="./references#CD008989-bbs2-0092" title="BeierJ , BeehKM . Long‐acting beta‐adrenoceptor agonists in the management of COPD: focus on indacaterol. International Journal of Chronic Obstructive Pulmonary Disease2011;6:237‐43. [1178‐2005: (Electronic)] ">Beier 2011</a>). Similarly, olodaterol binds to the receptor more tightly than salmeterol, forming an agonist‐receptor complex that lasts longer (<a href="./references#CD008989-bbs2-0096" title="CasarosaP , KollakI , KiechleT , OstermannA , SchnappA , KieslingR , et al. Functional and biochemical rationales for the 24‐hour‐long duration of action of olodaterol. Journal of Pharmacology and Experimental Therapeutics2011;337(3):600‐9. [PUBMED: 21357659] ">Casarosa 2011</a>). </p> <p>Independent of LABA type, stimulation of beta<sub>2</sub>‐receptors leads to changes in intracellular Ca<sup>2+</sup> homeostasis and bronchodilation (<a href="./references#CD008989-bbs2-0121" title="TanakaY , HorinouchiT , KoikeK . New insights into beta‐adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation. Clinical and Experimental Pharmacology and Physiology2005;32(7):503‐14. ">Tanaka 2005</a>). As with tiotropium, LABAs are used as 'symptom controllers' in stable COPD. One prior Cochrane review found that salmeterol improved lung function compared to placebo (<a href="./references#CD008989-bbs2-0089" title="AppletonS , PooleP , SmithB , VealeA , LassersonTJ , ChanMMK , et al. Long‐acting beta2‐agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD001104.pub2] ">Appleton 2006</a>). One more recent, large (3045 participants), long‐term (three‐year) RCT also compared salmeterol to placebo (TORCH; TOwards a Revolution in COPD Health) (<a href="./references#CD008989-bbs2-0095" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. ">Calverley 2007</a>). In this trial, salmeterol use was associated with an increase in lung function and a significant reduction in the annual rate of moderate or severe exacerbations compared with placebo (rate ratio 0.85, P value &lt; 0.001). One systematic review, which included the TORCH study and another 13 trials looking at salmeterol or formoterol (6453 participants), showed that treatment with a LABA reduced the rate of exacerbations and improved lung function and quality of life compared to placebo, but had no significant effect on mortality (<a href="./references#CD008989-bbs2-0118" title="RodrigoGJ , NanniniLJ , Rodríguez‐RoisinR . Safety of long‐acting β‐agonists in stable COPD. Chest2008;133(5):1079‐87. ">Rodrigo 2008</a>). There have also been studies on indacaterol and olodaterol showing improvements in lung function, quality of life, and exacerbations compared to placebo (<a href="./references#CD008989-bbs2-0110" title="KochA , PizzichiniE , HamiltonA , HartL , KorduckiL , DeSalvoMC , et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat(R) versus placebo and formoterol twice daily in patients with GOLD 2‐4 COPD: results from two replicate 48‐week studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:697‐714. [PUBMED: 25045258] ">Koch 2014</a>; <a href="./references#CD008989-bbs2-0112" title="MoenMD . Indacaterol: in chronic obstructive pulmonary disease. Drugs2010;70(17):2269‐80. [0012‐6667: (Print)] ">Moen 2010</a>). Possible adverse effects of LABAs include cardiac effects such as arrhythmia and palpitations, and muscle tremors, headache, cough, and dry mouth (<a href="./references#CD008989-bbs2-0091" title="BeehKM , BeierJ . Indacaterol, a novel inhaled, once‐daily, long‐acting beta2‐agonist for the treatment of obstructive airways diseases. Advances in Therapy2009;26(7):691‐9. [0741‐238X: (Print)] ">Beeh 2009</a>; <a href="./references#CD008989-bbs2-0093" title="BergerWE , NadelJA . Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2008;102(2):173‐88. [0954‐6111: (Print)] ">Berger 2008</a>). </p> </section> </section> <section id="CD008989-sec-0022"> <h3 class="title" id="CD008989-sec-0022">Why it is important to do this review</h3> <p>Both tiotropium and LABAs are recommended for treatment of stable COPD (<a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a>). However, people whose COPD is not adequately managed by either LABA or tiotropium treatment alone could potentially benefit from treatment with a combination of the two. It has been suggested that combination therapies directed at both adrenergic and muscarinic receptors could provide greater, and potentially additive, bronchodilation compared with a beta<sub>2</sub>‐agonist or a muscarinic antagonist alone (<a href="./references#CD008989-bbs2-0116" title="ProskocilBJ , FryerAD . Beta2‐agonist and anticholinergic drugs in the treatment of lung disease. Proceedings of the American Thoracic Society2005;2(4):305‐10. ">Proskocil 2005</a>). A number of trials have been published looking at the effect of adding tiotropium to LABA for treatment of COPD, and the clinical evidence to date suggests there may be benefits in combining the treatments without increasing adverse effects (<a href="./references#CD008989-bbs2-0097" title="CazzolaM , MolimardM . The scientific rationale for combining long‐acting beta2‐agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology and Therapeutics2010;23(4):257‐67. ">Cazzola 2010</a>). This review is necessary to specify and quantify the potential benefits from the combination treatment with LABA and tiotropium compared to the individual components alone. </p> <p>This review forms part of a suite of reviews on the various combinations of tiotropium, LABA, and ICS for the treatment of COPD. They include reviews comparing: adding ICS to tiotropium and LABA (<a href="./references#CD008989-bbs2-0105" title="KarnerC , CatesCJ . The effect of adding inhaled corticosteroids to tiotropium and long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 9. [DOI: 10.1002/14651858.CD009039.pub2] ">Karner 2011a</a>); triple therapy (ICS plus LABA plus and tiotropium) with either tiotropium alone or ICS plus LABA combination therapy (<a href="./references#CD008989-bbs2-0106" title="KarnerC , CatesCJ . Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD008532.pub2] ">Karner 2011b</a>); tiotropium versus LABA (<a href="./references#CD008989-bbs2-0100" title="ChongJ , KarnerC , PooleP . Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2; CD009157] ">Chong 2012</a>); and a combination of ICS plus LABA plus tiotropium versus tiotropium or ICS plus LABA alone (<a href="./references#CD008989-bbs2-0126" title="WelshEJ , CatesCJ , PooleP . Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, issue 5. [DOI: 10.1002/14651858.CD007891.pub3; CD007891] ">Welsh 2013</a>). These reviews have been summarised in a network analysis (<a href="./references#CD008989-bbs2-0109" title="KewKM , DiasS , CatesCJ . Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis. Cochrane Database of Systematic Reviews2014, issue 3. [DOI: 10.1002/14651858.CD010844.pub2] ">Kew 2014</a>). Ongoing reviews and updates are in preparation comparing the various permutations of these three drugs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008989-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008989-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008989-sec-0133">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008989-sec-0023"></div> <p>To compare the relative effects on markers of quality of life, exacerbations, symptoms, lung function and serious adverse events in people with COPD randomised to LABA plus tiotropium versus tiotropium alone; or LABA plus tiotropium versus LABA alone. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008989-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008989-sec-0024">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008989-sec-0134">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008989-sec-0024"></div> <section id="CD008989-sec-0025"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008989-sec-0026"> <h4 class="title">Types of studies</h4> <p>We included only RCTs with a parallel‐group design of at least 12 weeks' duration. We did not exclude studies on the basis of blinding. </p> </section> <section id="CD008989-sec-0027"> <h4 class="title">Types of participants</h4> <p>We included populations with a diagnosis of COPD. We only included studies that used an external set of criteria to screen participants for this condition (e.g. GOLD, American Thoracic Society (ATS), British Thoracic Society (BTS), Thoracic Society of Australia and New Zealand (TSANZ)). </p> </section> <section id="CD008989-sec-0028"> <h4 class="title">Types of interventions</h4> <p>We included participants who were randomised to receive inhaled LABA in addition to tiotropium bromide compared to participants receiving either inhaled tiotropium bromide alone or inhaled LABA alone. We allowed any formulation of LABA and tiotropium bromide. Participants were allowed ICS and other co‐medications provided they were not part of the randomised treatment. </p> </section> <section id="CD008989-sec-0029"> <h4 class="title">Types of outcome measures</h4> <section id="CD008989-sec-0030"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008989-list-0001"> <li> <p>Quality of life (measured with a validated scale for COPD, e.g. St George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Disease Questionnaire (CRQ)). </p> </li> <li> <p>Hospital admissions; all cause and due to exacerbations.</p> </li> <li> <p>Mortality; all‐cause.</p> </li> <li> <p>Disease‐specific mortality, if independently adjudicated.</p> </li> </ul> </p> </section> <section id="CD008989-sec-0031"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008989-list-0002"> <li> <p>Exacerbations; requiring short burst oral corticosteroids or antibiotics, or both.</p> </li> <li> <p>FEV<sub>1</sub>. </p> </li> <li> <p>Symptoms.</p> </li> <li> <p>All‐cause non‐fatal serious adverse events</p> </li> <li> <p>Disease‐specific serious adverse events, if independently adjudicated.</p> </li> <li> <p>Withdrawals.</p> </li> </ul> </p> </section> </section> </section> <section id="CD008989-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008989-sec-0033"> <h4 class="title">Electronic searches</h4> <p>The previous published version of this review included searches up to January 2012. The search period for this update is January 2012 to July 2015. </p> <p>We identified trials from the Cochrane Airways Group Specialised Register (CAGR) of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD008989-sec-0099">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy in <a href="./appendices#CD008989-sec-0105">Appendix 2</a>. </p> <p>We searched ClinicalTrials.gov in September 2011 and again in April 2015 for the update. The search terms are in <a href="./appendices#CD008989-sec-0108">Appendix 3</a>. All databases were searched from their inception and there was no restriction on language of publication. </p> </section> <section id="CD008989-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We searched the following manufacturer websites in September 2011: Boehringer Ingelheim (Spiriva, Spiriva Respimat); Pfizer (Spiriva); Novartis (indacaterol, formoterol); GlaxoSmithKline (salmeterol); and AstraZeneca (formoterol). We reviewed reference lists of all primary studies and review articles for additional references. </p> </section> </section> <section id="CD008989-sec-0035"> <h3 class="title" id="CD008989-sec-0035">Data collection and analysis</h3> <section id="CD008989-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two review authors screened the titles and abstracts of citations retrieved through literature searches and obtained those deemed potentially relevant. We assigned each reference to a study identifier and independently assessed them against the inclusion criteria of this review. </p> </section> <section id="CD008989-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>We extracted information from each study for the following characteristics.</p> <p> <ul id="CD008989-list-0003"> <li> <p>Design (design, total study duration and run‐in, number of study centres and location, withdrawals, date of study). </p> </li> <li> <p>Participants (number, mean age, age range, gender, COPD severity, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, exclusion criteria). </p> </li> <li> <p>Interventions (run‐in, intervention treatment and inhaler type, control treatment and inhaler type). </p> </li> <li> <p>Outcomes (primary and secondary outcomes specified and collected, time points reported).</p> </li> </ul> </p> <p>Two review authors extracted data from the studies into data collection forms. We discussed and resolved any discrepancies in the data, or consulted a third party where necessary. We transferred data from the data collection forms into Review Manager 5 (<a href="./references#CD008989-bbs2-0117" title="The Nordic Cochrane Centre; The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre; The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> </section> <section id="CD008989-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias according to recommendations outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for the following items (<a href="./references#CD008989-bbs2-0102" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p> <ul id="CD008989-list-0004"> <li> <p>Allocation sequence generation.</p> </li> <li> <p>Concealment of allocation.</p> </li> <li> <p>Blinding of participants and investigators.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> </ul> </p> <p>We noted other sources of bias. We graded each potential source of bias as low, high, or unclear risk of bias. </p> </section> <section id="CD008989-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <section id="CD008989-sec-0040"> <h5 class="title">Dichotomous data</h5> <p>We analysed dichotomous data variables (such as mortality and withdrawals) using ORs. If count data were not available as the number of participants experiencing an event, we analysed the data as continuous, time‐to‐event, or rate ratios, depending on how they were reported. This included the outcomes: hospital admissions, exacerbations, and serious adverse events. </p> </section> <section id="CD008989-sec-0041"> <h5 class="title">Continuous data</h5> <p>We analysed continuous outcome data (such as FEV<sub>1</sub> and quality of life) as fixed‐effect model mean differences (MD) when the same scale was used, and standardised mean differences when different scales were employed in different studies. MD based on the change from baseline was preferred over MD based on absolute values. </p> <p>If data were not available for the same time point in all studies, we used the closest time points. Alternatively, end of study was used as a time of analysis for all studies. We used intention‐to‐treat (ITT) analysis on outcomes from all randomised participants, where possible, for primary analyses. </p> </section> </section> <section id="CD008989-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed dichotomous data using participants as the unit of analysis (rather than events) to avoid counting the same participant more than once. </p> </section> <section id="CD008989-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data, where possible. We also considered the impact of the unknown status of participants who withdrew from the trials as part of the sensitivity analysis. </p> </section> <section id="CD008989-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the amount of statistical variation between the study results with the I<sup>2</sup> statistic measurement. </p> </section> <section id="CD008989-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We minimised reporting bias from non‐publication of studies or selective outcome reporting by using a broad search strategy, contacting study authors directly, and checking references of included studies. If we had found sufficient numbers of trials, we planned to inspect funnel plots visually. </p> </section> <section id="CD008989-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We combined dichotomous data using Mantel‐Haenszel ORs with 95% confidence intervals (CI), with a fixed‐effect model. Where events were rare, we employed the Peto OR (since this does not require a continuity correction for zero cells). </p> <p>Where treatment effects were reported as an MD with 95% CI or exact P value, we calculated the standard error, entered it with the MD and combined the results using a fixed‐effect Generic Inverse Variance (GIV) model in Review Manager 5 (<a href="./references#CD008989-bbs2-0117" title="The Nordic Cochrane Centre; The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre; The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> <p>We combined rate ratios and hazard ratios using a fixed‐effect GIV model.</p> <p>We would have calculated numbers needed to treat for an additional beneficial outcome from the pooled OR and its CI, and applied to appropriate levels of baseline risk. </p> <p>We presented the findings of our primary outcomes in a summary of findings table using GRADEPro software and recommendations in Section 8.5 and Chapter 12 of the <i>Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008989-bbs2-0102" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data to the meta‐analyses for the pre‐specified outcomes. We explained all decisions to downgrade or upgrade the quality of studies using footnotes. </p> </section> <section id="CD008989-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Studies were subgrouped, where possible, according to:</p> <p> <ul id="CD008989-list-0005"> <li> <p>type of LABA;</p> </li> <li> <p>severity of disease at baseline; and</p> </li> <li> <p>tiotropium formulation.</p> </li> </ul> </p> </section> <section id="CD008989-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the sensitivity of our primary outcomes to degree of bias by comparing the overall results with those exclusively from trials assessed as being at low risk of bias. We also compared the results from the fixed‐effect models with results from random‐effects models. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008989-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008989-sec-0049"></div> <section id="CD008989-sec-0050"> <h3 class="title">Description of studies</h3> <section id="CD008989-sec-0051"> <h4 class="title">Results of the search</h4> <p>The updated database search (covering articles published between January 2012 and November 2014) identified 104 references from the Cochrane Airways Group Database, and an additional 55 references in July 2015. Of these, we identified 53 as potentially relevant, which we obtained in full text for further assessment. Two publications referred to studies already included (<a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>; <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>). A further 11 were eligible, representing five studies (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>; <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>) (see <a href="./references#CD008989-sec-0123" title="">Characteristics of included studies</a> table). We excluded 58 full‐text records and added 10 studies to the <a href="./references#CD008989-bbs1-0003" title="">Studies awaiting classification</a> table. </p> <p>Searching ClinicalTrials.gov in April 2015 identified a further 209 records, none of which were eligible for inclusion. However, there were a number of completed but currently unpublished trials listed on ClinicalTrials.gov that may meet inclusion criteria in future iterations (four completed studies with 2148 participants enrolled; and one study that is still recruiting with an estimated enrolment of about 7800 participants). In addition, we added seven records to studies already identified (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a:</a> NCT01431274; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>: NCT01431287; <a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>: NCT00846586; <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>: NCT00877383; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>: NCT00134979; <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>: NCT01694771; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>: NCT01696058). </p> <p>The original database search in September 2011 identified 172 references and an additional five references in January 2012. Of these, 27 were defined as potentially relevant and were obtained in full text for further assessment. Eighteen of these were eligible and belonged to five studies (<a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>; <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>; <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>) (see <a href="./references#CD008989-sec-0123" title="">Characteristics of included studies</a> table). Searching the manufacturers' websites, we found study reports for three of the included studies (<a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>; <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). Searching ClinicalTrials.gov in September 2011 did not generate any additional eligible trials. For the study flow diagram, see <a href="#CD008989-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD008989-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008989-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008989-sec-0052"> <h4 class="title">Included studies</h4> <section id="CD008989-sec-0053"> <h5 class="title">Study design</h5> <p>The longest studies were <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>, and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> with a duration of one year, although nearly all the endpoints reported by <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> were after 24 weeks. The other studies had a duration of 24 weeks (<a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>), 16 weeks (<a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>, and 12 weeks of treatment (<a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>; <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>; <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>; <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>). They were all multi‐centre studies except for <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>, which was conducted in a single Japanese centre. The <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> study was conducted at 27 Canadian medical centres, <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> in 35 centres, <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a> and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> in 90 centres across the US, and five studies were conducted in a large number of study centres in several different countries (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>; <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). </p> </section> <section id="CD008989-sec-0054"> <h5 class="title">Sample size</h5> <p>A total of 10,894 participants were randomised to the relevant treatment arms in the included studies: LABA plus tiotropium (4796 participants), tiotropium alone (4829 participants), and LABA alone (1268 participants). </p> </section> <section id="CD008989-sec-0055"> <h5 class="title">Participants</h5> <p>The mean age of participants varied from 63 to 73 years. The gender distribution varied from 50% to 93% men. All studies included participants with moderate‐to‐severe COPD, although <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>, <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, and <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> also included participants with very severe COPD (FEV<sub>1</sub> less than 30% predicted) according to <a href="./references#CD008989-bbs2-0101" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015). ">GOLD</a> guideline definitions of COPD (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, by far the biggest studies included, provided a breakdown showing 88.6% were GOLD stage 2/3, with only 11.3% GOLD stage 4). The mean baseline lung function (FEV<sub>1</sub>) varied between 38% and 67% predicted across the studies. </p> </section> <section id="CD008989-sec-0056"> <h5 class="title">Interventions</h5> <p>All the included studies used tiotropium 18 μg (HandiHaler), one inhalation daily, except <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, which used tiotropium 2.5 or 5 μg (Respimat), one inhalation daily. In <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, the LABA used was salmeterol 25 μg/puff, two puffs twice daily using a pressurised metered‐dose inhaler and a spacer device. <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>, <a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>, and <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a> used indacaterol single‐dose dry powder inhaler (SDDPI, Breezhaler) at 150 μg once daily. <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> and <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> both used formoterol. In <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> the dose used was 12 μg twice daily (Foradil Aerolizer) and in <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> the dose was 10 μg twice daily (multi‐dose dry powder inhaler). <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>, <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>, and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> used olodaterol 5 μg once daily through SDDPI (Respimat). </p> </section> <section id="CD008989-sec-0057"> <h5 class="title">Permitted co‐treatment</h5> <p>In all 10 studies, participants were allowed to use rescue medication, when necessary, to relieve symptoms (inhaled salbutamol/albuterol). <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>, <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, <a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>, <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>, <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>, <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>, <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>, and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> permitted continued use of regimens of ICS that were stable prior to entry throughout the study. In <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, respiratory medications such as oxygen, anti‐leukotrienes, and methylxanthines were continued in all participant groups. <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> permitted temporary increases in the dose or addition of oral corticosteroids and methylxanthines; 10% of participants were reported as taking methylxanthines at baseline. Participants in the <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a> study were either newly diagnosed or discontinued the use of any COPD medications (specifically, two participants discontinued tiotropium). </p> </section> <section id="CD008989-sec-0058"> <h5 class="title">Outcomes</h5> <p>The primary outcome for <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> was the proportion of participants experiencing one or more COPD exacerbation. The primary outcome for <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> was FEV<sub>1</sub> measured two hours post‐dose at the end of the study. In <a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>, <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>, <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>, <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>, and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>, the primary outcome was post‐dose FEV<sub>1</sub>, but defined as the normalised area under the curve (AUC) for FEV<sub>1</sub> measured from zero to three hours post‐dose (<a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>), zero to four hours post‐dose (<a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>), or five minutes to eight hours post‐dose (<a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>; <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>) at the last visit. <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a> and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> had a co‐primary endpoint of trough FEV<sub>1</sub> at the last visit. <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> specified three primary endpoints, all measured at 24 weeks: trough FEV<sub>1</sub> (mean of the values one hour and 10 minutes prior to the dose of study medication); post‐dose FEV<sub>1</sub>, defined as AUC zero to three hours post‐dose; and total SGRQ score. In <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>, the primary outcome was change in pre‐specified airway dimensions as measured using computed tomography. </p> </section> <section id="CD008989-sec-0059"> <h5 class="title">Funding</h5> <p>The Canadian Institutes of Health Research and the Ontario Thoracic Society funded the <a href="http://archie.cochrane.org/sections/documents/view?document=68518396008378750040091006103521%26format=REVMAN#STD-Aaron-2007" target="_blank">Aaron 2007</a> study. Schering‐Plough (markets formoterol) funded the <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> study and Novartis (markets formoterol and indacaterol) funded <a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>, <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>, and <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>. Boehringer Ingelheim (markets olodaterol) funded <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>, <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>, and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>. The <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a> study was self funded. </p> </section> </section> <section id="CD008989-sec-0060"> <h4 class="title">Excluded studies</h4> <p>In this update, we retrieved full‐text articles for 58 studies that did not meet the eligibility criteria for the review (see <a href="./references#CD008989-sec-0124" title="">Characteristics of excluded studies</a> table). Thirty‐five references used a LAMA other than tiotropium, although a number of these had study designs that would have not met other eligibility criteria (the BRIGHT study: <a href="./references#CD008989-bbs2-0019" title="BeehKM , KornS , BeierJ , JadayelD , HenleyM , TylekJ , et al. QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study [Abstract]. Thorax2012;67 (Suppl 2):A147 [P191]. ">Beeh 2012</a>; <a href="./references#CD008989-bbs2-0020" title="BeehKM , KornS , BeierJ , JadayelD , HenleyM , D'AndreaP , et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respiratory Medicine2014;108(4):584‐92. ">Beeh 2014</a>; the SHINE study: <a href="./references#CD008989-bbs2-0013" title="BarnesN , BatemanE , GallagherN , GreenY , HortonR , HenleyM , et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A147‐8. ">Barnes 2012</a>; <a href="./references#CD008989-bbs2-0015" title="BatemanE , HashimotoS , GallagherN , GreenY , HortonR , HenleyM , et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax2012;67(Suppl 2):A148‐9. ">Bateman 2012a</a>; <a href="./references#CD008989-bbs2-0016" title="BatemanE , FergusonGT , BarnesN , GallagherN , GreenY , HortonR , et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal2012;40(Suppl 56):2810. ">Bateman 2012b</a>; <a href="./references#CD008989-bbs2-0017" title="BatemanED , WelteT , HashimotoS , GallagherN , GreenY , HortonR , et al. Dual bronchodilation with once‐daily QVA149 provides superior bronchodilation compared to its mono‐components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine2013;187:A4263. ">Bateman 2013a</a>; <a href="./references#CD008989-bbs2-0018" title="BatemanED , FergusonGT , BarnesN , GallagherN , GreenY , HenleyM , et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal2013;42(6):1484‐94. ">Bateman 2013b</a>; <a href="./references#CD008989-bbs2-0024" title="ChapmanKR , BatemanED , GallagherN , HuH , KimHJ , BanerjiD . Once‐daily QVA149 improves lung function, dyspnea and health status regardless of disease severity and prior medications: the SHINE study [Abstract]. Respirology2013;18(Suppl 4):31 [OS100]. ">Chapman 2013a</a>; <a href="./references#CD008989-bbs2-0025" title="ChapmanKR , BatemanED , GallagherN , HuH , BanerjiD . P234 QVA149 once daily improves lung function, dyspnoea and health status independent of prior medications and disease severity: the SHINE study. Thorax2013;68(Suppl 3):A182‐3. ">Chapman 2013b</a>; <a href="./references#CD008989-bbs2-0026" title="ChapmanK , BatemanE , GallagherN , HuH , BanerjiD . Once‐daily QVA149 improves lung function, dyspnea, and health status independent of disease severity and prior medications: the SHINE study. Chest2014;145. ">Chapman 2014</a>; <a href="./references#CD008989-bbs2-0034" title="FrithP , ThompsonP , WarkP , LindstromS , BatemanE . Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. Respirology2013;18(Suppl 2):20 [O041]. ">Frith 2013</a>; <a href="./references#CD008989-bbs2-0047" title="MezziK , Fedele MChenH , BanerjiD . LABA/LAMA dual bronchodilation as a paradigm shift in COPD therapy: overview of the QVA149 ignite program. Chest2014;145. ">Mezzi 2014a</a>; <a href="./references#CD008989-bbs2-0073" title="WarkP , ChapmanK , BatemanE , OlssonP , ChenH , BanerjiD , et al. Effect of QVA149 on lung function in the subgroup of patients. Respirology (Carlton, Vic.)2015;20:81. ">Wark 2015</a>; the SPARK study: <a href="./references#CD008989-bbs2-0012" title="BanerjiD , FedeleM , ChenH . Once‐daily dual bronchodilation with QVA149 reduces COPD exacerbations: results from the ignite program. Chest2014;145 (meeting abstracts):3. ">Banerji 2014</a>; <a href="./references#CD008989-bbs2-0030" title="DecramerM , WedzichaJA , SandstromT , NiewoehnerD , Fowler TaylorA , D'AndreaP , et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187 (meeting abstracts):A1479. ">Decramer 2013</a>; <a href="./references#CD008989-bbs2-0033" title="FickerJ , WedizichaJ , TaylorAF , D'AndreaP , ArrasateC , ChenH . QVA149 improves lung function and reduces exacerbations compared with tiotropium in patients with severe‐to‐very severe COPD: the SPARK study. Chest2014;145 (3 meeting abstracts). [NCT01120691] ">Ficker 2014</a>; <a href="./references#CD008989-bbs2-0048" title="MezziK , WedzichaJA , DecramerM , Fowler TaylorA , FogelR , ChenH , et al. QVA149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study [Abstract]. Proceedings of the 7th International Primary Care Respiratory Group (IPCRG) World Conference Athens. 2014. ">Mezzi 2014b</a>; <a href="./references#CD008989-bbs2-0074" title="WedzichaJA , DecramerM , FickerJH , NiewoehnerDE , SandströmT , TaylorAF , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‐blind, parallel‐group study. Lancet Respiratory Medicine2013;1(3):199‐209. ">Wedzicha 2013a</a>; <a href="./references#CD008989-bbs2-0075" title="WedzichaJA , DecramerM , FickerJ , NiewoehnerDE , SandstromT , Fowler TaylorA . Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine2013;187 (meeting abstracts):A2429. ">Wedzicha 2013b</a>; <a href="./references#CD008989-bbs2-0076" title="WedzichaJA , DecramerM , FickerJH , SandstromT , TaylorAF , D'AndreaP , et al. Qva149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study [Abstract]. American Journal of Respiratory and Critical Care Medicine2014;189:A3761. ">Wedzicha 2014a</a>; <a href="./references#CD008989-bbs2-0077" title="WedzichaJ , FickerJ , NiewohnerD , SandstromT , Fowler TaylorA , BanerjiD . Dual bronchodilation with once‐daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe‐to‐very severe COPD patients: the SPARK study. Chest2014;145(3):406A. ">Wedzicha 2014b</a>; <a href="./references#CD008989-bbs2-0078" title="WedzichaJ , FickerJ , Fowler TaylorA , D'AndreaP , ArrasateC , ChenH , et al. Once‐daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe‐to‐very severe COPD: the SPARK study. Chest2014;145(3):427A. ">Wedzicha 2014c</a>; <a href="./references#CD008989-bbs2-0079" title="WedzichaJA , D'UrzoA , MezziK , ChenH , BanerjiD , FogelR . QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: the SPARK study [Abstract]. European Respiratory Journal2014;44(Suppl 58):1893. ">Wedzicha 2014d</a>; the BLAZE study: <a href="./references#CD008989-bbs2-0027" title="D'UrzoA , MahlerDA , DecramerM , WorthH , WhiteT , AlagappanVKT , et al. Superior lung function with once‐daily QVA149 translates into improvements in patient‐reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study. Thorax2013;68:P236. [DOI: 10.1136/thoraxjnl‐2013‐204457.388] ">D'Urzo 2013</a>; <a href="./references#CD008989-bbs2-0028" title="D'UrzoA , MahlerD , WorthH , WhiteT , AlagappanV , ChenH , et al. Once‐daily QVA149 demonstrates superior improvements in patient‐reported dyspnea compared to tiotropium in patients with moderate‐to‐severe COPD: the BLAZE study. Chest2014;145 (3 meeting abstract). ">D'Urzo 2014a</a>; <a href="./references#CD008989-bbs2-0029" title="D'UrzoA , MahlerD , WorthH , WhiteT , AlagappanV , ChenH , et al. Patients with severe COPD show significant improvements in dyspnea and lung function with once‐daily QVA149: the BLAZE study. Chest2014;145 (3 meeting abstracts). ">D'Urzo 2014b</a>; <a href="./references#CD008989-bbs2-0043" title="MahlerDA , DecramerM , D'UrzoAD , WorthH , WhiteT , AlagappanV , et al. Superior lung function with once‐daily QVA149 translates into improvements in patient‐reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study. American Journal of Respiratory and Critical Care Medicine2013;187:A6070. ">Mahler 2013</a>; <a href="./references#CD008989-bbs2-0044" title="MahlerDA , DecramerM , D'UrzoA , WorthH , WhiteT , AlagappanVKT , et al. Dual bronchodilation with QVA149 reduces patient‐reported dyspnoea in COPD: the BLAZE study. European Respiratory Journal2014;43(6):1599‐609. ">Mahler 2014</a>; other studies: <a href="./references#CD008989-bbs2-0021" title="BeierJ , vanNoordJ , DeansA , BrooksJ , MadenC , BaggenS , et al. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. International Journal of Chronic Obstructive Pulmonary Disease2012;7:153‐64. ">Beier 2012</a>; <a href="./references#CD008989-bbs2-0045" title="Maleki‐YazdiMR , KaelinT , RichardN , ZvarichM , ChurchA . Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg. Respiratory Medicine2014;108(12):1752‐60. ">Maleki‐Yazdi 2014</a>; <a href="./references#CD008989-bbs2-0056" title="NCT01285492 . A 52‐week treatment, multi‐center, randomized, open label, parallel group study to assess the long term safety and tolerability of QVA149 (110 mcg indacaterol / 50 mcg glycopyrrolate o.d.) using tiotropium (18 mcg o.d.) as an active control in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01285492 (accessed 15 April 2015). ">NCT01285492</a>; <a href="./references#CD008989-bbs2-0062" title="NicoliniA . Short term effects of tiotropium on COPD patients treated with long acting bronchodilators. Tanaffos2012;11(1):26‐31. ">Nicolini 2012</a>; <a href="./references#CD008989-bbs2-0063" title="OrevilloC , GotfriedM , DenenbergM , FernandezC , DarkenP , StRoseE , et al. Combination glycopyrronium and formoterol fumarate inhalation aerosol (PT003) at a dose of 14.4/9.6 µg provides superior improvement in inspiratory capacity compared to tiotropium dry powder inhaler (DPI) in subjects with moderate to severe COPD (Abstract). American Journal of Respiratory and Critical Care Medicine2014;189:A3759. ">Orevillo 2014</a>; <a href="./references#CD008989-bbs2-0064" title="ReisnerC , FernandezC , OrevilloC , St. RoseE , KollarC . Pearl therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva(R) HandiHaler(R) and placebo in patients with COPD. Proceedings of the American Thoracic Society 2012 International Conference, 2012 May 18‐23; San Francisco, California. 2012:A2926. ">Reisner 2012a</a>; <a href="./references#CD008989-bbs2-0065" title="ReisnerC , RennardSI , FogartyC , FischerT , StRoseE , FernandezC , et al. Pearl Therapeutics' combination LAMA/LABA MDI (GFF‐MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared io its components administered alone, Spiriva(R) Handihaler(R), and Foradil(R) Aerolizer(R) in a randomized, double‐blind, placebo‐controlled phase 2b study in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2259. ">Reisner 2012b</a>; <a href="./references#CD008989-bbs2-0066" title="ReisnerC , GotfriedM , DenenbergMB , FernandezC , StRoseE , FortnerP , et al. Low doses of Pearl Therapeutics' LAMA/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open‐label Spiriva HandiHaler in a randomized, double‐blind, placebo‐controlled phase IIb study in patients with COPD. American Journal of Respiratory and Critical Care Medicine2013;187 (meeting abstracts):A2434. ">Reisner 2013</a>). </p> <p>Nine references were for studies with a duration of fewer than 12 weeks (<a href="./references#CD008989-bbs2-0023" title="CantoND , RibeiroJP , NederJA , ChiappaGR . Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD. Respiratory Medicine2012;106(10):1404‐12. ">Canto 2012</a>; <a href="./references#CD008989-bbs2-0031" title="DeromE , WestermanJ , GronkeL , HamiltonA , LiC , BeehKM . The 24‐hour lung function profile of once‐daily tiotropium and olodaterol fixed‐dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease. Thorax2014;69:A190‐1. ">Derom 2014</a>; <a href="./references#CD008989-bbs2-0036" title="FujimotoK , YamazakiH , UraM , KitaguchiY . Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD [Abstract]. European Respiratory Journal2014;44(Suppl 58):P897. ">Fujimoto 2014a</a>; <a href="./references#CD008989-bbs2-0037" title="FujimotoK , YamazakiH , UraM . Efficacy of mono‐therapy with tiotropium or indacaterol or the. Respirology (Carlton, Vic.)2014;19(Suppl 3):101. ">Fujimoto 2014b</a>; <a href="./references#CD008989-bbs2-0040" title="ImranM , ChhabraSK , KotwaniA . Combinations of long acting beta2 agonists to. Archives of Pharmacy Practice2015;6(2):19‐23. ">Imran 2015</a>; <a href="./references#CD008989-bbs2-0062" title="NicoliniA . Short term effects of tiotropium on COPD patients treated with long acting bronchodilators. Tanaffos2012;11(1):26‐31. ">Nicolini 2012</a>; <a href="./references#CD008989-bbs2-0067" title="SalviS , BrashierB , GothiD , KarkhanisV , MadasS , GogtayJ , et al. Bronchodilator efficacy of tiotropium‐formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD. Pulmonary Pharmacology and Therapeutics2014;27(1):90‐5. ">Salvi 2014</a>; <a href="./references#CD008989-bbs2-0068" title="SetoguchiY . The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status [Abstract]. European Respiratory Journal2014;44(Suppl 58):P896. ">Setoguchi 2014</a>; <a href="./references#CD008989-bbs2-0069" title="TashkinDP , HananiaNA , McGintyJ , Denis‐MizeK , ChaudryI . Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Advances in Therapy2009;26(11):1024‐34. ">Tashkin 2009b</a>), three of these and a further three references reported studies with a cross‐over design (<a href="./references#CD008989-bbs2-0011" title="AalbersR , Maleki‐YazdiMR , HamiltonA , Waitere‐WijkerS , PivovarovaA , SchmidtO , et al. Dose‐finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD. European Respiratory Journal2012;40(Suppl 56):P2882. ">Aalbers 2012</a>; <a href="./references#CD008989-bbs2-0023" title="CantoND , RibeiroJP , NederJA , ChiappaGR . Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD. Respiratory Medicine2012;106(10):1404‐12. ">Canto 2012</a>; <a href="./references#CD008989-bbs2-0039" title="HorhotaST , vanNoordJA , VerkleijCB , BourLJ , SharmaA , TrunkM , et al. In vitro, pharmacokinetic, pharmacodynamic, and safety comparisons of single and combined administration of tiotropium and salmeterol in COPD patients using different dry powder inhalers. AAPS Journal2015;17(4):871‐80. ">Horhota 2015</a>; <a href="./references#CD008989-bbs2-0041" title="JayaramL , WongC , McAuleyS , ReaH , ZengI , O'DochartaighC . Combined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: effect on the 6‐minute walk test. Journal of Chronic Obstructive Pulmonary Disease2013;10(4):466‐72. ">Jayaram 2013</a>; <a href="./references#CD008989-bbs2-0067" title="SalviS , BrashierB , GothiD , KarkhanisV , MadasS , GogtayJ , et al. Bronchodilator efficacy of tiotropium‐formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD. Pulmonary Pharmacology and Therapeutics2014;27(1):90‐5. ">Salvi 2014</a>; <a href="./references#CD008989-bbs2-0068" title="SetoguchiY . The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status [Abstract]. European Respiratory Journal2014;44(Suppl 58):P896. ">Setoguchi 2014</a>). </p> <p>Of the records retrieved from ClinicalTrials.gov that were not already included, nine were for studies with a duration of fewer than 12 weeks (<a href="./references#CD008989-bbs2-0049" title="NCT00394485 . Tiotropium + procaterol vs tiotropium + placebo in COPD patients. clinicaltrials.gov/show/NCT00394485 (accessed 15 April 2015). [NCT00394485] ">NCT00394485</a>; <a href="./references#CD008989-bbs2-0050" title="NCT00424528 . Efficacy safety study of arformoterol/tiotropium combination versus either therapy alone in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT00424528 (accessed 15 April 2015). [NCT00424528] ">NCT00424528</a>; <a href="./references#CD008989-bbs2-0052" title="NCT00673478 . Tiotropium and salmeterol PK study in COPD patients. clinicaltrials.gov/show/NCT00673478 (accessed 15 April 2015). [NCT00673478] ">NCT00673478</a>; <a href="./references#CD008989-bbs2-0053" title="NCT00680056 . Add‐on effects of tiotropium over formoterol in exercise tolerance on chronic obstructive pulmonary disease patients. clinicaltrials.gov/show/NCT00680056 (accessed 15 April 2015). [NCT00680056] ">NCT00680056</a>; <a href="./references#CD008989-bbs2-0054" title="NCT00696020 . Combination of orally inhaled BI1744CL/tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT00696020 (accessed 15 April 2015). [NCT00696020] ">NCT00696020</a>; <a href="./references#CD008989-bbs2-0055" title="NCT01040403 . Determining optimal free dose combination of tiotropium bromide and BI 1744 CL in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01040403 (accessed 15 April 2015). [NCT01040403] ">NCT01040403</a>; <a href="./references#CD008989-bbs2-0057" title="NCT01559116 . Characterization of 24‐hour lung function profiles of inhaled tiotropium + olodaterol fixed dose combination in patients suffering from chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT01559116 (accessed 15 April 2015). [NCT01559116] ">NCT01559116</a>; <a href="./references#CD008989-bbs2-0058" title="NCT02238119 . Efficacy and safety of free combination of tiotropium + formoterol compared to formoterol and tiotropium in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT02238119 (accessed 15 April 2015). [NCT02238119] ">NCT02238119</a>; <a href="./references#CD008989-bbs2-0060" title="NCT02242253 . Free combinations of tiotropium inhalation powder capsule + salmeterol metered dose inhaler, tiotropium inhalation powder capsule and salmeterol metered dose inhaler in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT02242253 (accessed 15 April 2015). [NCT02242253] ">NCT02242253</a>), one had a cross‐over design (<a href="./references#CD008989-bbs2-0059" title="NCT02242240 . Lung function changes following the addition of formoterol to tiotropium in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT02242240 (accessed 15 April 2015). [NCT02242240] ">NCT02242240</a>), and one had been terminated (<a href="./references#CD008989-bbs2-0051" title="NCT00668772 . Tiotropium/salmeterol inhalation powder in COPD. clinicaltrials.gov/show/NCT00668772 (accessed 15 April 2015). [NCT00668772] ">NCT00668772</a>). </p> <p>In the original review, 11 studies did not meet the eligibility criteria for the review (see <a href="./references#CD008989-sec-0124" title="">Characteristics of excluded studies</a> table). Seven of these compared tiotropium alone compared with a LABA but had no treatment arm with a combination of the two (<a href="./references#CD008989-bbs2-0014" title="BatemanED , HodderR , MiravitllesM , LeeA , TowseL , SerbyC . A comparative trial of tiotropium, salmeterol and placebo: health‐related quality of life. European Respiratory Journal2001;18(Suppl 33):26s. ">Bateman 2001</a>; <a href="./references#CD008989-bbs2-0022" title="BrusascoV , MenjogeSS , KestenS . Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 420. ">Brusasco 2003</a>; <a href="./references#CD008989-bbs2-0032" title="DiMarcoF , CarlucciP , CazzolaM , VergaM , MondoniM , PistoneA , et al. A single dose of formoterol (FOR) and tiotropium (TIO) reduce hyperinflation in COPD patients [Abstract]. European Respiratory Journal2003;22(Suppl 45):P1844. ">Di Marco 2003</a>; <a href="./references#CD008989-bbs2-0035" title="FujimotoK , KomatsuY , KandaS , ItouM , YoshikawaS , YasuoM , et al. Comparison of clinical efficacy of tiotropium and salmeterol for pulmonary function, air‐trapping, exercise capacity, and HRQO in COPD [Abstract]. Respirology2007;12(Suppl 4):A164. ">Fujimoto 2007</a>; <a href="./references#CD008989-bbs2-0038" title="GrossNJ , PaulsonD , KennedyD , KorduckiL , KestenS . A comparison of maintenance tiotropium and salmeterol on arterial blood gas tensions in patients with COPD [Abstract]. Respiratory Care2003;48(11):1081. ">Gross 2003</a>; <a href="./references#CD008989-bbs2-0046" title="MeyerT , BrandP , ReitmeirP , ScheuchG . Effect of formoterol, salbutamol and tiotropium bromide on the efficacy of lung clearance in patients with COPD [Abstract]. Proceedings of the American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2008:A646[#F1]. ">Meyer 2008</a>; <a href="./references#CD008989-bbs2-0070" title="tenHackenNH , van derHaartH , GrevinkR , ThompsonS , RoemerW , PostmaDS . Bronchodilation improves endurance but not muscular efficiency in COPD [Abstract]. Proceedings of the American Thoracic Society International Conference; 2007 May 18‐23; San Francisco2007:Poster #M72. ">ten Hacken 2007</a>). Six studies were of cross‐over design (<a href="./references#CD008989-bbs2-0038" title="GrossNJ , PaulsonD , KennedyD , KorduckiL , KestenS . A comparison of maintenance tiotropium and salmeterol on arterial blood gas tensions in patients with COPD [Abstract]. Respiratory Care2003;48(11):1081. ">Gross 2003</a>; <a href="./references#CD008989-bbs2-0042" title="JonesCDS . The combined effect of tiotropium and formoterol on the functional status of patients with moderate‐to‐severe COPD [Dissertation]. CINAHL Accession Number: 2011033276//UMI Order AAI34089302010:144 p. [978‐112‐405‐5602602] ">Jones 2010</a>; <a href="./references#CD008989-bbs2-0046" title="MeyerT , BrandP , ReitmeirP , ScheuchG . Effect of formoterol, salbutamol and tiotropium bromide on the efficacy of lung clearance in patients with COPD [Abstract]. Proceedings of the American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2008:A646[#F1]. ">Meyer 2008</a>; <a href="./references#CD008989-bbs2-0070" title="tenHackenNH , van derHaartH , GrevinkR , ThompsonS , RoemerW , PostmaDS . Bronchodilation improves endurance but not muscular efficiency in COPD [Abstract]. Proceedings of the American Thoracic Society International Conference; 2007 May 18‐23; San Francisco2007:Poster #M72. ">ten Hacken 2007</a>; <a href="./references#CD008989-bbs2-0071" title="VanNoordJ , AumannJ , JanssensE , MuellerA , CornelissenP . Relation between the acute response to salbutamol and long term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T=F) in COPD patients [abstract]. European Respiratory Journal2003;22(Suppl 45):153. vanNoordJA , QumannJ , JanssensE , MuellerA , CornelissenPJ . Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. Proceedings of the American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle2003:B024 Poster 421. ">van Noord 2003</a>; <a href="./references#CD008989-bbs2-0072" title="vanNoordJA , SmeetsJJ , OtteA , BindelsH , MuellerA , CornellissenPJG . The effect of tiotropium, salmeterol and it's combination on dynamic hyperinflation in COPD [Abstract]. Proceedings of the American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego, California. 2005:[B93] [Poster: 310]. ">van Noord 2005</a>), and seven had a treatment period shorter than 12 weeks (<a href="./references#CD008989-bbs2-0035" title="FujimotoK , KomatsuY , KandaS , ItouM , YoshikawaS , YasuoM , et al. Comparison of clinical efficacy of tiotropium and salmeterol for pulmonary function, air‐trapping, exercise capacity, and HRQO in COPD [Abstract]. Respirology2007;12(Suppl 4):A164. ">Fujimoto 2007</a>; <a href="./references#CD008989-bbs2-0038" title="GrossNJ , PaulsonD , KennedyD , KorduckiL , KestenS . A comparison of maintenance tiotropium and salmeterol on arterial blood gas tensions in patients with COPD [Abstract]. Respiratory Care2003;48(11):1081. ">Gross 2003</a>; <a href="./references#CD008989-bbs2-0046" title="MeyerT , BrandP , ReitmeirP , ScheuchG . Effect of formoterol, salbutamol and tiotropium bromide on the efficacy of lung clearance in patients with COPD [Abstract]. Proceedings of the American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2008:A646[#F1]. ">Meyer 2008</a>; <a href="./references#CD008989-bbs2-0061" title="NewJ , HananiaN , MatovinovicE , TashkinD . Adding nebulized formoterol to tiotropium treatment provides added benefits in pulmonary function, dyspnea and rescue medication use: a pooled analysis [Abstract]. Proceedings of the American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A4541 [Poster #J51]. ">New 2009</a>; <a href="./references#CD008989-bbs2-0070" title="tenHackenNH , van derHaartH , GrevinkR , ThompsonS , RoemerW , PostmaDS . Bronchodilation improves endurance but not muscular efficiency in COPD [Abstract]. Proceedings of the American Thoracic Society International Conference; 2007 May 18‐23; San Francisco2007:Poster #M72. ">ten Hacken 2007</a>; <a href="./references#CD008989-bbs2-0071" title="VanNoordJ , AumannJ , JanssensE , MuellerA , CornelissenP . Relation between the acute response to salbutamol and long term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T=F) in COPD patients [abstract]. European Respiratory Journal2003;22(Suppl 45):153. vanNoordJA , QumannJ , JanssensE , MuellerA , CornelissenPJ . Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. Proceedings of the American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle2003:B024 Poster 421. ">van Noord 2003</a>; <a href="./references#CD008989-bbs2-0072" title="vanNoordJA , SmeetsJJ , OtteA , BindelsH , MuellerA , CornellissenPJG . The effect of tiotropium, salmeterol and it's combination on dynamic hyperinflation in COPD [Abstract]. Proceedings of the American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego, California. 2005:[B93] [Poster: 310]. ">van Noord 2005</a>). </p> <p>Four references were for abstracts with insufficient data and therefore we classed them as awaiting assessment but did not exclude them from this analysis (<a href="./references#CD008989-bbs2-0080" title="EvdokimovV , EvdokimovaA , TebloevK , ZolotovaO . Clinical efficacy and safety of tiotropium and indacaterol administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease. European Journal of Heart Failure Abstracts Supplement2014;16(Suppl 2):251. ">Evdokimov 2014a</a>; <a href="./references#CD008989-bbs2-0081" title="EvdokimovV , EvdokimovaA , TebloevK , KovalenkoE , KozhinaN , ZolotovaO . Efficacy and safety of different types of bronchodilator therapy in patients with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease. European Heart Journal2014;35:385‐6. ">Evdokimov 2014b</a>; <a href="./references#CD008989-bbs2-0082" title="EvdokimovV , EvdokimovaA , SheyanovM , KozhinaN . Clinical efficacy and safety of formoterol and tiotropium administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease. European Journal of Heart Failure2015;17(Suppl 1):68. ">Evdokimov 2015;</a><a href="./references#CD008989-bbs2-0088" title="SadigovA , AkhundovS , BagirovR . Analysis of chronic obstructive pulmonary disease exacerbations with the triple therapy compared with dual and single bronchodilator therapy: which treatment is better for patients with severe disease?. Chest2014;145(3):425A. ">Sadigov 2014</a>). A further three studies were eligible but results had not been published (<a href="./references#CD008989-bbs2-0084" title="NCT01536262 . Japan long‐term safety for tiotropium plus olodaterol. clinicaltrials.gov/show/NCT01536262 (accessed 15 April 2015). [NCT01536262] ">NCT01536262</a>; <a href="./references#CD008989-bbs2-0085" title="NCT01964352 . Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 1). clinicaltrials.gov/show/NCT01964352 (accessed 15 April 2015). [NCT01964352] ">NCT01964352</a>; <a href="./references#CD008989-bbs2-0086" title="NCT02006732 . Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 2). clinicaltrials.gov/show/NCT02006732 (accessed 15 April 2015). [NCT02006732] ">NCT02006732</a>), one had been published but only in two abstracts (NCT01525615; <a href="./references#CD008989-bbs2-0083" title="MaltaisF , Galdiz IturriJB , KirstenA , SinghD , HamiltonA , TetzlaffK , et al. Effects of 12 weeks of once‐daily tiotropium and olodaterol fixed‐dose combination on exercise endurance in patients with COPD. Thorax. BMJ Publishing Group, 2014; Vol. 69:A186‐7. MaltaisF , IturriJBG , KirstenA , SinghD , HamiltonA , TetzlaffK , et al. Effects of 12 weeks of once‐daily tiotropium and olodaterol fixed‐dose combination on exercise endurance in patients with COPD. European Respiratory Journal. European Respiratory Society, 2014; Vol. 44. NCT01525615 . A study to determine the effect of tiotropium + olodaterol fixed dose combination on exercise endurance time during constant work load cycle test in COPD. clinicaltrials.gov/show/NCT01525615 (accessed 15 April 2015). [NCT01525615] ">Maltais 2014</a>), and one was still recruiting (<a href="./references#CD008989-bbs2-0087" title="NCT02296138 . Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT02296138 (accessed 15 April 2015). [NCT02296138] ">NCT02296138</a>). We classed these as awaiting assessment and will revisit them in the next iteration of this review (see <a href="./references#CD008989-sec-0125" title="">Characteristics of studies awaiting classification</a> table). </p> </section> </section> <section id="CD008989-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>The <a href="./references#CD008989-sec-0123" title="">Characteristics of included studies</a> table presents an assessment of the risk of bias, and <a href="#CD008989-fig-0004">Figure 4</a> presents an overview of the findings. </p> <div class="figure" id="CD008989-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (note: not all studies compared long‐acting beta2‐agonists (LABA) plus tiotropium (TIO) versus LABA and this means that these have empty squares in the fourth column)." data-id="CD008989-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (note: not all studies compared long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium (TIO) versus LABA and this means that these have empty squares in the fourth column). </p> </div> </div> </div> <section id="CD008989-sec-0062"> <h4 class="title">Allocation</h4> <p>Nine of the 10 studies reported adequate sequence generation, through a computer‐generated system, and allocation concealment. <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a> did not include details of allocation and blinding in their article, and were unavailable to provide further information. Information from <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> and <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>/<a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> was kindly supplied on request. In <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, <a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>, <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>, <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>, <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>, and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> randomisation data were kept strictly confidential until the time of unblinding, and was not accessible by anyone involved in the study before or after randomisation. In <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>, the randomisation code was labelled on the medication kit. </p> </section> <section id="CD008989-sec-0063"> <h4 class="title">Blinding</h4> <p>The blinding in <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> was adequate. In <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, both research staff and participants were blinded to the treatment assignment until the end of the study. The different inhalers were identical in appearance and they were enclosed in tamper‐proof blinding devices. Clinical data for suspected exacerbations were reviewed by a blinded committee and the statistician who performed the analysis was initially blinded to participant group assignments. In the <a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>, <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>, <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>, and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> trials, participants, investigator staff, people performing the assessments, data analysts, and the trial teams were all blinded. <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> were also double‐blind studies. </p> <p>The <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> study was partially blinded with tiotropium being administered open‐label, but double‐blind for the LABA treatment. The risk of performance bias was therefore high for the comparison LABA plus tiotropium versus LABA alone, and low for LABA plus tiotropium versus tiotropium alone. The risk of detection bias was also low as outcome assessors and data analysts were blinded to participant group assignments. Information from <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> was kindly supplied on request. <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a> also ran an open‐label trial but noted that airway dimensions were measured in a blind fashion; it is unclear if other outcome measurements (e.g. lung function) were also made blinded and we could not reach the authors for further information. </p> <p><a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> did not fully describe who was blinded in the study report. </p> </section> <section id="CD008989-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> had high withdrawal rates in the different study groups (74 participants (47%) withdrew from the tiotropium plus placebo group and 64 participants (43%) on LABA plus tiotropium). For most participants, data were recorded throughout the one‐year trial period regardless of whether participants discontinued treatment with study medications. The rates of participants who stopped therapy and did not complete the trial were 30 participants (19%) taking tiotropium plus placebo and 20 participants (14%) taking LABA plus tiotropium. Mortality data were obtained for all participants with the exception of two out of 148 participants (1.4%) taking LABA plus tiotropium and four out of 156 participants (2.6%) taking tiotropium plus placebo, who withdrew and declined further study. </p> <p>In <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>, <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, and <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>, the number of withdrawals was also uneven but was relatively low. For <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>, there were more withdrawals in the LABA plus tiotropium group than tiotropium alone (14.5% with LABA plus tiotropium versus 6.1% with tiotropium alone). But in <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, attrition was higher among participants on monotherapy (LABA or tiotropium) rather than combination treatment. As withdrawn participants are more likely to have unfavourable outcomes, one would expect the direction of bias to underestimate the true treatment effect of combination therapy (<a href="./references#CD008989-bbs2-0108" title="KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. ">Kesten 2007</a>). </p> <p><a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a> only provided the overall drop‐out rate, which was relatively low (13%), but it was unclear if this was even across groups. </p> <p>In the other five studies, the number of withdrawals in the different groups were relatively low and even (<a href="./references#CD008989-bbs2-0005" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00846586 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586] ">Mahler 2010a</a>: 6.8% with LABA plus tiotropium versus 6.2% with tiotropium; <a href="./references#CD008989-bbs2-0006" title="A randomized, double‐blind, controlled, parallel group, 12‐week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate‐to‐severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341] BalkissoonR . Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439‐41. MahlerDA , D'UrzoA , BatemanED , OzkanSA , WhiteT , PeckittC , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double‐blind comparison. Thorax2012;67(9):781‐8. [PUBMED: 22544891] MahlerDA , D'UrzoA , PeckittC , LassenC , KramerB , FilcekS . Combining once‐daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13‐18, Denver, Colorado. 2011:183. NCT00877383 . Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383] ">Mahler 2010b</a>: 5.1% with LABA plus tiotropium versus 6.5% with tiotropium; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>: 12% with LABA plus tiotropium versus 12% with LABA versus 13% with tiotropium; <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>: 7.05% with LABA plus tiotropium versus 7.08% with tiotropium; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>: 7.60% with LABA plus tiotropium versus 5.45% with tiotropium). </p> </section> <section id="CD008989-sec-0065"> <h4 class="title">Selective reporting</h4> <p>All the included studies adequately reported outcome data for the primary and secondary outcomes that they had pre‐specified in the study records, but we did not compare reported outcomes to the trial protocols. </p> </section> </section> <section id="CD008989-sec-0066"> <h3 class="title" id="CD008989-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD008989-tbl-0001"><b>Summary of findings for the main comparison</b> Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus tiotropium alone</a>; <a href="./full#CD008989-tbl-0002"><b>Summary of findings 2</b> Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus long‐acting beta<sub>2</sub>‐agonist alone</a> </p> <section id="CD008989-sec-0067"> <h4 class="title">Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus tiotropium alone </h4> <p>We subgrouped the data in the forest plots according to type of LABA. However, these need to be interpreted with caution because of the small number of trials and the many significant differences between them, including length of study. We planned to analyse the data using subgroups for disease severity and tiotropium formulation, but were unable to compare subgroups given the small number of trials and the overwhelming contribution of participants from trials of olodaterol. </p> <section id="CD008989-sec-0068"> <h5 class="title">Primary outcome: quality of life</h5> <p>Six studies (6709 participants) reported changes in quality of life using the SGRQ; <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>, <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>, and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>, were only able to provide aggregate data combining both studies. In the forest plot (<a href="./references#CD008989-fig-0009" title="">Analysis 1.1</a>), the aggregate data from <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>, and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> are shown under "ZuWallack 2014a", whereas the aggregate data for <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> is split by the dose of tiotropium used i.e. the data point labelled "Buhl 2015a" is the pooled data from both studies (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>) for tiotropium at a dose of 2.5 μg, while the entry labelled "Buhl 2015b" is the pooled data for tiotropium at a dose of 5 μg). The studies added different LABAs to tiotropium: these were salmeterol (<a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007)</a>, formoterol (<a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>), and olodaterol (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>), and these are shown as separate subgroups in the forest plot (<a href="./references#CD008989-fig-0009" title="">Analysis 1.1</a>). It should be noted that the majority of the data now comes from participants randomised to olodaterol. </p> <p>A decrease in SGRQ score denotes an improvement in quality of life and a difference of at least four units is regarded as clinically significant (<a href="./references#CD008989-bbs2-0119" title="JonesP . St George's Respiratory Questionnaire for COPD patients (SGRQ‐C). www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ‐C%20uk%20orig%202005.pdf (accessed 9 July 2015). ">SGRQ‐C manual 2008</a>). <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> showed an improvement in quality of life in the control arm, tiotropium alone, of ‐4.5 units after one year. The pooled result of the treatment difference between LABA plus tiotropium and tiotropium alone showed that the combination treatment led to a statistically significant ‐1.34 unit improvement in quality of life (95% CI ‐1.87 to ‐0.80 units, see <a href="#CD008989-fig-0005">Figure 5</a>; this equates to a cumulative improvement of ‐5.8 versus baseline, using the control from <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>). </p> <div class="figure" id="CD008989-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.1 Change in quality of life." data-id="CD008989-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.1 Change in quality of life. </p> </div> </div> </div> <p>While the CI of this MD excludes the minimal clinically important difference (MCID) of four units, four studies included a responder analysis showing a pooled 1646/3008 (54.7%) participants had a response of better than four units taking the combination versus 1421/2970 (47.8%) participants taking tiotropium alone (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>; <a href="./references#CD008989-fig-0010" title="">Analysis 1.2</a>), as shown in the Cates plot in <a href="./full#CD008989-fig-0001">Figure 1</a>. There is additional uncertainty in relation to the quality of life in those participants who withdrew from the study. </p> </section> <section id="CD008989-sec-0069"> <h5 class="title">Primary outcome: hospital admissions</h5> <p>Four studies (4856 participants) reported the number of participants who were admitted to hospital for any cause and separately, hospitalisations for exacerbations (<a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). Data for <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> and <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> were kindly supplied on request. The number of hospitalised participants were similar and there was no statistically significant differences between the treatment groups for hospitalisations for any cause (OR 1.01, 95% CI 0.86 to 1.19; <a href="./references#CD008989-fig-0011" title="">Analysis 1.3</a>; <a href="#CD008989-fig-0006">Figure 6</a>) or due to exacerbation (OR 1.02, 95% CI 0.80 to 1.28; <a href="./references#CD008989-fig-0012" title="">Analysis 1.4</a>; <a href="#CD008989-fig-0007">Figure 7</a>). There was uncertainty arising from the potential additional admissions that were not known in the participants who withdrew. </p> <div class="figure" id="CD008989-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.3 Hospital admission (all cause)." data-id="CD008989-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.3 Hospital admission (all cause). </p> </div> </div> </div> <div class="figure" id="CD008989-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.4 Hospital admission (exacerbation)." data-id="CD008989-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.4 Hospital admission (exacerbation). </p> </div> </div> </div> </section> <section id="CD008989-sec-0070"> <h5 class="title">Primary outcome: mortality (all causes)</h5> <p>Nine out of 10 studies (9633 participants) reported mortality for formoterol, salmeterol, indacaterol, and olodaterol. However, there were no deaths during the study periods in <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> and <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>. In the remaining seven studies, there was no statistically significant difference between the treatment groups as the number of events was low, leading to relatively wide CIs for the difference between the groups (Peto OR 1.24, 95% CI 0.81 to 1.90; <a href="./references#CD008989-fig-0013" title="">Analysis 1.5</a>; <a href="#CD008989-fig-0008">Figure 8</a>). Moreover, there were considerably more participants who discontinued treatment than the numbers who died, adding further uncertainty to the true impact on mortality. </p> <div class="figure" id="CD008989-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.5 Mortality (all cause)." data-id="CD008989-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.5 Mortality (all cause). </p> </div> </div> </div> </section> <section id="CD008989-sec-0071"> <h5 class="title">Secondary outcome: exacerbations</h5> <p>Seven studies (6391 participants), of formoterol, salmeterol and olodaterol, reported the number of participants experiencing one or more exacerbation during the study period (<a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>; <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>). <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> defined exacerbations as a sustained worsening of the participant's respiratory condition, from the stable state and beyond normal day‐to‐day variations, necessitating a change in regular medication in a person with underlying COPD. <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> reported the number of participants experiencing COPD exacerbations, defined as COPD‐related adverse events (AEs) requiring additional therapy, where COPD‐related AEs were in turn defined as AEs coding to the preferred terms: COPD, COPD exacerbated, cough, any term containing 'dyspnoea', lower respiratory tract infection, chronic bronchitis, bronchospasm, bronchial obstruction, and respiratory failure; and additional therapy was any COPD therapy reported as being used to treat a COPD exacerbation, other than rescue bronchodilator. <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> did not describe the definition of exacerbation, but it stated that most participants who needed treatment for their exacerbations received antibiotics alone or a course of antibiotics and systemic corticosteroids. <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>, <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>, and <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> also did not define an exacerbation, but reported "COPD" as an adverse event (according to Medical Dictionary for Regulatory Activities (MedDRA) classifications). </p> <p>The baseline risk also varied greatly between the studies. In the one‐year studies, a high proportion of participants on tiotropium alone experienced one or more exacerbations: from 32.4% in <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and 33.3% in <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, to 62.8% in <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>. In the shorter studies, the number was 10.7% (<a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>), 10.4% (<a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>), 10.8% (<a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>), and 9.7% (<a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>). There was also substantial heterogeneity between the studies (I<sup>2</sup> = 43%) and the exacerbation status of the participants who withdrew from each study was unknown. In <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>, more participants experienced exacerbations in the LABA plus tiotropium group (OR 1.70, 95% CI 0.82 to 3.52). <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> showed the opposite result (OR 0.58, 95% CI 0.28 to 1.17), as did <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> in the treatment arms using tiotropium 2.5 μg(OR 0.80, 95% CI 0.66 to 0.96). There was little difference between the treatment arms using tiotropium 5 μg alone or in combination (OR 0.97, 95% CI 0.81 to 1.17; <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>), or in the groups in <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> (OR 1.09, 95% CI 0.68 to 1.75), <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a> (OR 1.24, 95% CI 0.86 to 1.78), or <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a> (OR 0.95, 95% CI 0.63 to 1.41). In a sensitivity analysis, <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> reported a similar result when assuming that all participants who were lost to follow‐up had an exacerbation (OR 0.87, 95% CI 0.52 to 1.45). We did not pool the results for this outcome due to the clinical heterogeneity between the studies. </p> </section> <section id="CD008989-sec-0072"> <h5 class="title">Secondary outcome: lung function (pre‐dose forced expiratory volume in one second)</h5> <p>All 10 studies (9573 participants) reported lung function. Eight of the studies considered different measures of post‐bronchodilator FEV<sub>1</sub> as their primary outcome, but all 10 also reported pre‐bronchodilator FEV<sub>1</sub> values. The improvement in pre‐bronchodilator FEV<sub>1</sub> at the end of the study showed a statistically significant increase in the LABA plus tiotropium group compared to the tiotropium alone group (MD 0.06, 95% CI 0.05 to 0.07; <a href="./references#CD008989-fig-0015" title="">Analysis 1.7</a>). The improvement in FEV<sub>1</sub> in the control arm, tiotropium alone, after six months of treatment was 0.13 L in <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> and 0.03 L after one year in <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>. Data for both <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> and <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> were kindly supplied on request. </p> </section> <section id="CD008989-sec-0073"> <h5 class="title">Secondary outcome: symptom score</h5> <p>Both <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> and <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> reported changes in symptom scores. However, we were unable to obtain standard deviations for the data from <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>. <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> used a total daily symptom score that was the sum of the scores for breathlessness, cough, wheeze, amount of sputum, and colour of sputum. Each were scored on a scale from zero to three where zero was equal to no symptoms. <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> kindly supplied data on request that showed a large uncertainty and no statistically significant difference between the treatment groups in total symptom score (MD 0.21, 95% CI ‐0.30 to 0.72; <a href="./references#CD008989-fig-0016" title="">Analysis 1.8</a>). </p> </section> <section id="CD008989-sec-0074"> <h5 class="title">Secondary outcome: serious adverse events (non‐fatal)</h5> <p>Nine studies (9654 participants) reported the number of participants experiencing serious, but non‐fatal, adverse events during the study period, for which there was no statistically significant difference (OR 1.07, 95% CI 0.93 to 1.23; <a href="./references#CD008989-fig-0017" title="">Analysis 1.9</a>). Data for <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> were kindly supplied on request. It appeared that <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> and <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> included COPD primary outcome data in the serious adverse events but <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> did not. </p> </section> <section id="CD008989-sec-0075"> <h5 class="title">Secondary outcome: withdrawal</h5> <p>Nine studies (9654 participants) reported the number of withdrawals from study medication in each treatment group. Most of the studies had relatively even withdrawal rates and there was no statistically significant difference between the treatment groups (OR 0.92, 95% CI 0.75 to 1.14; <a href="./references#CD008989-fig-0018" title="">Analysis 1.10</a>). However, notable exceptions were the two largest trials, <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, which found significantly higher withdrawal rates in the groups taking tiotropium alone versus LABA plus tiotropium, at both the 5 μg dose of tiotropium (combined results from both trials: 168/1033 (16.2%) with tiotropium alone versus 133/1029(12.9%) with LABA plus tiotropium) and 2.5 μg dose (175/1032(17.0%) with tiotropium alone versus 123/1030 (11.9%) with LABA plus tiotropium). Given that people who discontinue clinical trials are more likely to have had worse outcomes, this suggests that the potential benefit of LABA plus tiotropium has been underestimated (<a href="./references#CD008989-bbs2-0108" title="KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. ">Kesten 2007</a>). <a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a> reported the opposite results (12% with LABA plus tiotropium versus 6% with tiotropium alone), but was a smaller trial (255 participants). Together these results introduced moderate heterogeneity in the pooled result (I<sup>2</sup> = 54%). </p> </section> </section> <section id="CD008989-sec-0076"> <h4 class="title">Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus long‐acting beta<sub>2</sub>‐agonist alone </h4> <p>Four studies (3552 participants) compared LABA plus tiotropium versus LABA alone (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> were double blind, but in <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a> and <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>, tiotropium was administered open‐label thus this comparison was not blinded. The LABAs studied were formoterol (<a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008)</a>, indacaterol (<a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>), and olodaterol (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>). Again, we subgrouped the data in the forest plots according to type of LABA, but were unable to compare subgroups given the small number of trials and the overwhelming contribution of participants from trials taking olodaterol. </p> <p>Note that the total number of participants varies as data were not provided for all participants for each outcome in the two largest studies (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>). Specifically, SGRQ data was only provided for 2923/3097 participants randomised and trough FEV<sub>1</sub> data for 3058/3097 participants. The total numbers of participants included each analysis are given at the start of each section. </p> <section id="CD008989-sec-0077"> <h5 class="title">Primary outcome: quality of life</h5> <p>All four studies (3378 participants) reported changes in quality of life by SGRQ score (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> were only able to provide aggregate data, which were split into those treatment arms using the lower 2.5 μg dose of tiotropium versus the higher 5 μg dose. There was a statistically significant improvement in SGRQ of 1.25 units (MD ‐1.25, 95% CI ‐2.14 to ‐0.37; <a href="./references#CD008989-fig-0019" title="">Analysis 2.1</a>), which is less than the MCID of four units. However, in the two studies that included a responder analysis, 1090/1969 (55.4%) participants taking LABA plus tiotropium demonstrated a response above the MCID of four units, compared to 427/954 (44.8%) participants taking LABA alone (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-fig-0020" title="">Analysis 2.2</a>) as shown in the Cates plot in <a href="./full#CD008989-fig-0002">Figure 2</a>. </p> </section> <section id="CD008989-sec-0078"> <h5 class="title">Primary outcome: hospital admissions</h5> <p>Three out of four studies (3514 participants) reported the number of participants who were admitted to hospital for any cause and separately, hospitalisations for exacerbations (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). Data for <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> was kindly supplied on request. The number of hospitalised participants were similar and there was no statistically significant differences between the treatment groups for hospitalisations for any cause (OR 0.93, 95% CI 0.76 to 1.14; <a href="./references#CD008989-fig-0021" title="">Analysis 2.3</a>) or due to exacerbation (OR 0.90, 95% CI 0.66 to 1.22; <a href="./references#CD008989-fig-0022" title="">Analysis 2.4</a>). There was uncertainty arising from the potential additional admissions that were not known in the participants who withdrew. </p> </section> <section id="CD008989-sec-0079"> <h5 class="title">Primary outcome: mortality (all cause)</h5> <p>Three out of four studies (3514 participants) reported mortality (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>), although there were no deaths during the study period in <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>. In the remaining two studies, there was no statistically significant difference between the treatment groups as the number of events was low, leading to relatively wide CIs for the difference between the groups (Peto OR 1.15, 95% CI 0.62 to 2.13; <a href="./references#CD008989-fig-0023" title="">Analysis 2.5</a>). As previously discussed, considerably more participants discontinued treatment than the numbers who died, adding further uncertainty to the true impact on mortality. </p> </section> <section id="CD008989-sec-0080"> <h5 class="title">Secondary outcome: exacerbations</h5> <p>Three out of four studies (3514 participants) reported the number of participants experiencing one or more exacerbation during the study period (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). There was a significantly lower risk of exacerbation using a combination of LABA plus tiotropium versus LABA alone (OR 0.80, 95% CI 0.69 to 0.93; <a href="./references#CD008989-fig-0024" title="">Analysis 2.6</a>). Although only the combination inhalers using the lower 2.5 μg dose of tiotropium achieved significance (OR 0.75, 95% CI 0.60 to 0.93 with 2.5 μg dose compared to OR 0.86, 95% CI 0.69 to 1.07 with 5 μg dose) in the pooled results of <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, the pooled result was significant and there was little heterogeneity to suggest that this was not valid. </p> </section> <section id="CD008989-sec-0081"> <h5 class="title">Secondary outcome: lung function (pre‐dose forced expiratory volume in one second)</h5> <p>All four studies (3513 participants) reported pre‐bronchodilator FEV<sub>1</sub> values. The improvement in pre‐bronchodilator FEV<sub>1</sub> at the end of the study showed a modest but statistically significant increase in the LABA plus tiotropium group compared to the LABA alone group (MD 0.07, 95% CI 0.06 to 0.09; <a href="./references#CD008989-fig-0025" title="">Analysis 2.7</a>). </p> </section> <section id="CD008989-sec-0082"> <h5 class="title">Secondary outcome: serious adverse events (non‐fatal), withdrawal</h5> <p>All four studies (3552 participants) reported the number of participants experiencing serious, but non‐fatal, adverse events during the study period (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>), although there were none recorded in <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>. For the remaining studies, there was no statistically significant difference between the treatment groups (OR 0.94, 95% CI 0.77 to 1.14; <a href="./references#CD008989-fig-0026" title="">Analysis 2.8</a>). Data for <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a> were kindly supplied on request. </p> </section> <section id="CD008989-sec-0083"> <h5 class="title">Secondary outcome: withdrawal</h5> <p>Three out of four studies (3514 participants) reported the number of withdrawals from study medication in each treatment group (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). There were significantly higher withdrawal rates in the groups on LABA alone versus LABA plus tiotropium (OR 0.66, 95% CI 0.52 to 0.83; <a href="./references#CD008989-fig-0027" title="">Analysis 2.9</a>). This was driven by the results of the two larger trials (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>), where 195/1038 (18.8%) participants were withdrawn in the olodaterol arms across both studies, compared to 123/1030 (11.9%) of participants taking tiotropium 2.5 μg plus olodaterol 5 μg and 133/1029 (12.9%) in participants taking tiotropium 5 μg plus olodaterol 5 μg). As alluded to above, the higher rate of withdrawals in the olodaterol only group is likely to underestimate the benefit of combination treatment with olodaterol plus tiotropium. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008989-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008989-sec-0084">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008989-sec-0142">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008989-sec-0084"></div> <section id="CD008989-sec-0085"> <h3 class="title" id="CD008989-sec-0085">Summary of main results</h3> <p>This systematic review set out to investigate the long‐term (three months or longer) effects of tiotropium in combination with LABA compared to either LABA alone or tiotropium alone, for the treatment of COPD. We identified 10 randomised, parallel‐group, placebo‐controlled trials with 10,894 participants. All 10 studied the effects of tiotropium in combination with LABA compared to tiotropium alone, whereas only four of these studies also looked at combination treatment compared to LABA alone (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). </p> <section id="CD008989-sec-0086"> <h4 class="title">Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus tiotropium alone </h4> <p>This review found that compared to tiotropium alone, treatment with tiotropium plus LABA resulted in a slightly larger improvement in the mean health‐related quality of life (SGRQ: MD ‐1.34, 95% CI ‐1.87 to ‐0.80). With tiotropium alone it improved by ‐4.5 units from baseline in one study (<a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>), thus this represented a cumulative change from baseline of ‐5.8 units with both treatments. The mean improvement of ‐1.3 units with combined therapy (tiotropium plus LABA) versus tiotropium alone was small in relation to the threshold of four units for a clinically significant difference, and was reflected in 54.7% of participants who had a response of better than four units on combination (versus 47.8% with tiotropium alone; <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>). There were no significant differences in the other primary outcomes (hospital admissions and mortality). Pre‐bronchodilator FEV<sub>1</sub> showed a modest but statistically significant improvement with tiotropium plus LABA compared to tiotropium alone. None of the other secondary outcomes (exacerbations, symptom scores, serious adverse events, and withdrawals) showed any statistically significant difference between the groups. However, there was moderate heterogeneity for both exacerbations and withdrawals. </p> </section> <section id="CD008989-sec-0087"> <h4 class="title">Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus long‐acting beta<sub>2</sub>‐agonist alone </h4> <p>Four studies (3552 participants) compared LABA plus tiotropium versus LABA (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a>; <a href="./references#CD008989-bbs2-0008" title="ArievichH , PotenaA , FonayK , VogelmeierCF , OverendT , SmithJ , et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal2006;28(Suppl 50):440s [P2514]. NCT00134979 . Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979] Novartis . A randomized, multi‐center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402] VogelmeierC , KardosP , HarariS , GansSJ , StengleinS , ThirlwellJ . Formoterol mono‐ and combination therapy with tiotropium in patients with COPD: a 6‐month study. Respiratory Medicine2008;102(11):1511‐20. VogelmeierCF , HarariSA , FonayK , BeierJ , OverendT , TillD , et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal2006;28(Suppl 50):429s [P2506]. ">Vogelmeier 2008</a>). As with the analyses comparing combination therapy to tiotropium alone, there was a small but significant advantage of combination therapy in terms of SGRQ (MD ‐1.25, 95% CI ‐2.14 to ‐0.37) and pre‐bronchodilator FEV<sub>1</sub> (MD 0.07, 95% CI 0.06 to 0.09). In addition, there was a significant reduction in exacerbation rates when adding tiotropium to a LABA (OR 0.80, 95% CI 0.69 to 0.93). This was despite a higher rate of withdrawals in the LABA monotherapy arm, which would bias the result against combination therapy. </p> </section> </section> <section id="CD008989-sec-0088"> <h3 class="title" id="CD008989-sec-0088">Overall completeness and applicability of evidence</h3> <p>The lack of clear differences in effect between the treatment groups for many of the outcomes may be due to the relatively short treatment duration, with nine out of 10 studies reporting outcomes at 24 weeks or less. This led to fewer events and low power to detect any differences. For continuous outcomes such as lung function, quality of life, and symptom scores, studies with a duration of less than six months may not provide enough time to reach a steady state, which may also influence the result in a conservative way. However, we noted that the two largest trials, <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, reported outcomes at one year on ClinicalTrials.gov, which were in keeping with the findings at 24 weeks that they published (we used the 24‐week results in the analysis as these were the pre‐specified primary endpoints, were included in the journal publication, and are more closely comparable to the other studies included). </p> <p>The results from this review indicate a small improvement in the mean health‐related quality of life and lung function for participants on a combination of LABA plus tiotropium compared to either drug alone. The mean improvement for both outcomes was statistically significant but relatively small in relation to the MCID for each outcome. However, there may still be a significant minority of participants who have a clinically relevant improvement compared to the number with a clinically relevant deterioration, as was the case in four studies (<a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a>; <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>; <a href="./references#CD008989-bbs2-0009" title="AbrahamsR , AllenL , HernandezG , TingN , ZuWallackR . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418] NCT01694771 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014a</a>; <a href="./references#CD008989-bbs2-0010" title="AbrahamsR , AllenL , HernandezG , TingN , WallackRZ . Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12‐week studies. Chest. 2014 (4 meeting abstracts):47A. NCT01696058 . Co‐administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058] ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double‐blind studies. Chest2014;146 (4 meeting abstracts):70A. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double‐blind, active‐controlled studies. International Journal of Chronic Obstructive Pulmonary Disease2014;9:1133‐44. ZuWallackR , AllenL , HernandezG , TingN , AbrahamsR . Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double‐blind studies. International Journal of Chronic Obstructive Pulmonary Disease2014;146 (4 meeting abstracts):46A. ">ZuWallack 2014b</a>). This type of responder analysis may be a useful additional way of measuring health‐related quality of life. </p> <p>The severity of COPD in the participants studied varied quite considerably, with a mean baseline FEV<sub>1</sub> between 38% and 67% predicted. <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> noted that people with a lower baseline FEV<sub>1</sub> (i.e. more severe disease) showed smaller responses to treatment in clinical trials, thus potential differences may have been missed in trials that predominantly recruited participants with severe disease. It also impacts on the applicability of these findings: the largest trials in our analysis, <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a>, provided a breakdown of participants showing that the vast majority (88.6%) had moderately severe COPD (GOLD stage 2/3). Thus, the findings contained are likely to apply to people with moderately severe disease, but less so to those with severe COPD (GOLD stage 4). </p> <p>The use of ICS is potentially a confounder, and all of the studies except for <a href="./references#CD008989-bbs2-0004" title="HoshinoM . Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology2014;44(Suppl 58):4668. HoshinoM , OhtawaJ . Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology2014;19:403‐10. ">Hoshino 2014</a> included participants receiving ICS with the proportion on ICS at baseline varying between 27% (<a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>) and 78% (<a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>). <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> performed a subgroup analysis showing the benefit of combination therapy over monotherapy in terms of lung function (pre‐ and post‐dose FEV<sub>1</sub>) was independent of ICS use; in their studies, 2446/5162 (47.4%) participants were on ICS at baseline. This suggests that the findings of this review may apply to both people taking ICS and people not receiving ICS, although there is no direct evidence on outcomes other than lung function. </p> <p>The withdrawal rates were low and broadly comparable for combined and monotherapy treatments for most of the studies, but unexpectedly higher in the monotherapy groups in <a href="./references#CD008989-bbs2-0002" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431274 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274] ">Buhl 2015a</a> and <a href="./references#CD008989-bbs2-0003" title="BuhlR , AbrahamsR , BjermerL , DeromE , FlezarM , HebertJ , et al. Pooled safety analysis of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1‐year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts). BuhlR , DeromE , FergusonG , PizzichiniE , ReidJ , WatzH , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes versus mono‐components in COPD in two 1‐year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188‐9. BuhlR , MaltaisF , AbrahamsR , BjermerL , DeromE , FergusonG , et al. Tiotropium and olodaterol fixed‐dose combination versus mono‐components in COPD (GOLD 2‐4). European Respiratory Journal2015;45(4):969‐79. [PUBMED: 25573406] ChiaM , ReidJ , BuhlR , AbrahamsR , BjermerL , DeromE , et al. Safety of once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat in chronic obstructive pulmonary disease in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. ChiaM , ReidJ , BuhlR , DeromE , FergusonG , MaltaisF , et al. Once‐daily tiotropium and olodaterol fixed‐dose combination via the Respimat improves outcomes vs mono‐components in COPD in two 1‐year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77. NCT01431287 . Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287] ">Buhl 2015b</a> (the largest studies representing about half of our total sample). Given that people who discontinue clinical trials are more likely to have had worse outcomes (<a href="./references#CD008989-bbs2-0108" title="KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30(5):898‐906. ">Kesten 2007</a>), this suggests that, if anything, the potential benefit of combined therapy has been underestimated. </p> </section> <section id="CD008989-sec-0089"> <h3 class="title" id="CD008989-sec-0089">Quality of the evidence</h3> <p>We encountered statistical heterogeneity in two outcomes when combination therapy was compared to tiotropium alone: COPD exacerbations (I<sup>2</sup> = 43%) and the number of participants withdrawing from the studies (I<sup>2</sup> = 66%). This could be from one or more of several sources, such as the differences in definition of exacerbation and the length of the studies. The smallest study to report withdrawal rates had more uneven withdrawal rates compared with the other studies (<a href="./references#CD008989-bbs2-0007" title="NCT00139932 . Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932] TashkinD , VargheseS . Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S4 [13]. TashkinD , VargheseS . The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12‐week, multicenter, double‐blind, placebo‐controlled, trial. Chest2007;132(4):529a. TashkinDP . Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto2008:A647[#F5]. TashkinDP , PearleJ , IezzoniD , VargheseST . Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(1):17‐25. TashkinDP , PearleJL , VargheseS . Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008;134(4):103002s. ">Tashkin 2009a</a>, 255 participants). </p> <p>The GRADE assessment for the primary outcomes was moderate, due to the risk of attrition bias (more withdrawals in the single‐therapy arms). </p> </section> <section id="CD008989-sec-0090"> <h3 class="title" id="CD008989-sec-0090">Potential biases in the review process</h3> <p>We are aware that there are further relevant studies listed on ClinicalTrials.gov and several abstracts that have not yet published results. This is potentially a source of publication bias. </p> </section> <section id="CD008989-sec-0091"> <h3 class="title" id="CD008989-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>In addition to the long‐term (three months' or longer duration) studies presented in this review there have been several studies looking at acute and short‐term (up to six weeks) effects of tiotropium plus LABA compared to tiotropium or LABA alone (e.g. <a href="./references#CD008989-bbs2-0097" title="CazzolaM , MolimardM . The scientific rationale for combining long‐acting beta2‐agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology and Therapeutics2010;23(4):257‐67. ">Cazzola 2010</a>). One short‐term, parallel‐group study also looked at health‐related quality of life using the SGRQ (<a href="./references#CD008989-bbs2-0123" title="TashkinDP , LittnerM , AndrewsCP , TomlinsonL , RinehartM , Denis‐MizeK . Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo‐controlled trial. Respiratory Medicine2008;102(4):479‐87. ">Tashkin 2008b</a>). After six weeks' treatment, they found no difference between tiotropium plus LABA compared to tiotropium alone. However, at least for LABA it may take up to six months of treatment to reach a steady state and to see the full effect on quality of life (<a href="./references#CD008989-bbs2-0095" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. ">Calverley 2007</a>). </p> <section id="CD008989-sec-0092"> <h4 class="title">Cost effectiveness</h4> <p>The cost effectiveness of tiotropium plus LABA treatment compared to both tiotropium alone and triple therapy consisting of ICS plus LABA combination inhaler plus tiotropium has been assessed for the <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> study (<a href="./references#CD008989-bbs2-0113" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a>). The setting for this one‐year study was within the Canadian healthcare system and the cost‐effectiveness evaluation was based on 2006 prices. In this study, treatment with tiotropium plus LABA resulted in both higher costs and a higher rate of exacerbations than treatment with tiotropium alone. However, when focusing on people with severe COPD tiotropium plus LABA resulted in equal exacerbation rates and slightly lower costs compared to tiotropium alone, although there was considerable uncertainty around this result. Therefore, based on <a href="./references#CD008989-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, tiotropium on its own is the most cost‐effective treatment compared to tiotropium plus LABA when looking at the incremental cost for exacerbations avoided and per additional quality‐adjusted life year. However, for a chronic illness such as COPD a cost‐effectiveness study of one year is unlikely to capture all relevant costs and benefits. </p> <p>We did not revisit the cost‐effectiveness analysis for the updated review.</p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008989-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="On tiotropium/olodaterol combination, at six months there were 55 SGRQ (St George's Respiratory Questionnaire) responders out of 100 (95% confidence interval 52 to 57) compared to 48 out of 100 on tiotropium alone." data-id="CD008989-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>On tiotropium/olodaterol combination, at six months there were 55 SGRQ (St George's Respiratory Questionnaire) responders out of 100 (95% confidence interval 52 to 57) compared to 48 out of 100 on tiotropium alone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="With tiotropium/olodaterol combination there were 55 SGRQ (St George's Respiratory Questionnaire) responders out of 100 (95% confidence interval 51 to 59) compared to 45 out of 100 with olodaterol alone." data-id="CD008989-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>With tiotropium/olodaterol combination there were 55 SGRQ (St George's Respiratory Questionnaire) responders out of 100 (95% confidence interval 51 to 59) compared to 45 out of 100 with olodaterol alone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008989-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (note: not all studies compared long‐acting beta2‐agonists (LABA) plus tiotropium (TIO) versus LABA and this means that these have empty squares in the fourth column)." data-id="CD008989-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (note: not all studies compared long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium (TIO) versus LABA and this means that these have empty squares in the fourth column). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.1 Change in quality of life." data-id="CD008989-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.1 Change in quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.3 Hospital admission (all cause)." data-id="CD008989-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.3 Hospital admission (all cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.4 Hospital admission (exacerbation)." data-id="CD008989-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.4 Hospital admission (exacerbation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.5 Mortality (all cause)." data-id="CD008989-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, outcome: 1.5 Mortality (all cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 1 Change in quality of life." data-id="CD008989-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 1 Change in quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 2 Quality of life St George's Respiratory Questionnaire responder analysis." data-id="CD008989-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 2 Quality of life St George's Respiratory Questionnaire responder analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 3 Hospital admission (all cause)." data-id="CD008989-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 3 Hospital admission (all cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 4 Hospital admission (exacerbation)." data-id="CD008989-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 4 Hospital admission (exacerbation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 5 Mortality (all cause)." data-id="CD008989-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 5 Mortality (all cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 6 Exacerbation." data-id="CD008989-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 6 Exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 7 Trough forced expiratory volume in 1 second (FEV1) (L)." data-id="CD008989-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 7 Trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 8 Symptom score." data-id="CD008989-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 8 Symptom score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 9 Serious adverse event (non‐fatal)." data-id="CD008989-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 9 Serious adverse event (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 10 Withdrawal." data-id="CD008989-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus tiotropium alone, Outcome 10 Withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 1 Change in quality of life." data-id="CD008989-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 1 Change in quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 2 Quality of life St George's Respiratory Questionnaire responder analysis." data-id="CD008989-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 2 Quality of life St George's Respiratory Questionnaire responder analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 3 Hospital admission (all cause)." data-id="CD008989-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 3 Hospital admission (all cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 4 Hospital admission (exacerbation)." data-id="CD008989-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 4 Hospital admission (exacerbation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 5 Mortality (all cause)." data-id="CD008989-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 5 Mortality (all cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 6 Exacerbation." data-id="CD008989-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 6 Exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 7 Trough forced expiratory volume in one second (FEV1) (L)." data-id="CD008989-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 7 Trough forced expiratory volume in one second (FEV<sub>1</sub>) (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 8 Serious adverse event (non‐fatal)." data-id="CD008989-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 8 Serious adverse event (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008989-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/urn:x-wiley:14651858:media:CD008989:CD008989-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_t/tCD008989-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 9 Withdrawal." data-id="CD008989-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Long‐acting beta<sub>2</sub>‐agonists (LABA) plus tiotropium versus LABA alone, Outcome 9 Withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/media/CDSR/CD008989/image_n/nCD008989-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008989-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Long‐acting beta2‐agonist plus tiotropium versus tiotropium alone</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus tiotropium alone for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> LABA + tiotropium<br/> <b>Comparison:</b> tiotropium </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tiotropium</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LABA + tiotropium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in quality of life<br/> assessed with: SGRQ<br/> Scale from 0 to 100 (lower score is better) </p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life at 6 months was <b>‐5.7 units</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>1.34 units lower</b> (1.87 lower to 0.8 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6709<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Better quality of life on combination treatment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life SGRQ responder analysis at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 100</b> <br/> (52 to 57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.32<br/> (1.19 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5978<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="./full#CD008989-fig-0001">Figure 1</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (all cause)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> <br/> (12 to 16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.01<br/> (0.86 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4856<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (exacerbation)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> <br/> (5 to 8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.02<br/> (0.80 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4856<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (all cause)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (7 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.24<br/> (0.81 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9633<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in trough FEV<sub>1</sub> (L) </p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in trough FEV<sub>1</sub> at 6 months was <b>0.06 L</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in trough FEV<sub>1</sub> in the intervention group was <b>0.06 L more</b> (0.05 more to 0.07 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9573<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonist; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SGRQ:</b> St George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> More drop‐outs with tiotropium alone </p> <p><sup>2</sup> Width of 95% CI limits our confidence in this outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Long‐acting beta2‐agonist plus tiotropium versus tiotropium alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008989-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Long‐acting beta2‐agonist plus tiotropium versus long‐acting beta2‐agonist alone</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Long‐acting beta<sub>2</sub>‐agonist plus tiotropium versus long‐acting beta<sub>2</sub>‐agonist alone for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> addition to tiotropium versus either tiotropium or long‐acting beta<sub>2</sub>‐agonist alone for chronic obstructive pulmonary disease<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> LABA plus tiotropium<br/> <b>Comparison:</b> LABA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LABA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LABA plus tiotropium</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in quality of life<br/> assessed with: SGRQ<br/> Scale from 0 to 100 (lower score is better) </p> <p>Follow‐up: range 312 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life at 6 months was <b>‐5.7 units</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>1.25 units lower</b> (2.14 lower to 0.37 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3378<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Better quality of life on combination treatment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life SGRQ responder analysis at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 100</b> <br/> (51 to 59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.53<br/> (1.31 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2923<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="./full#CD008989-fig-0002">Figure 2</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (all cause)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> <br/> (11 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.93<br/> (0.76 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3514<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (exacerbation)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> <br/> (4 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.90<br/> (0.66 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3514<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (all cause)</p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (7 to 24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.15<br/> (0.62 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3514<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in trough FEV<sub>1</sub> (L) </p> <p>Follow‐up: range 3‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in trough FEV<sub>1</sub> at 6 months was <b>0.05 L</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean trough FEV<sub>1</sub> in the intervention group was <b>0.07 L more</b> (0.06 more to 0.09 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3513<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonist; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SGRQ:</b> St George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> More drop‐outs on LABA alone </p> <p><sup>2</sup> Width of 95% CI limits our confidence in this outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Long‐acting beta2‐agonist plus tiotropium versus long‐acting beta2‐agonist alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/full#CD008989-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008989-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.87, ‐0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.8 [‐3.32, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐3.70, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Olodaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐1.86, ‐0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life St George's Respiratory Questionnaire responder analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.19, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Olodaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.19, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospital admission (all cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.86, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.61, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.36, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Olodaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hospital admission (exacerbation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.80, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.66, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.15, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Olodaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.77, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality (all cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.81, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.45, 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Indacaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.26, 8.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Olodaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.75, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.68, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.34, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Olodaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.05, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.07, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.02, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Indacaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.06, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Olodaterol vs. tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.03, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Olodaterol vs. tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.04, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Olodaterol vs. tiotropium 18 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.03, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Symptom score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious adverse event (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.93, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.37, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.54, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Indacaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.72, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Olodaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.75, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.54, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.52, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Indacaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.65, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Olodaterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.65, 1.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Long‐acting beta2‐agonists (LABA) plus tiotropium versus tiotropium alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008989-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.25 [‐2.14, ‐0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.03 [‐2.36, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.69 [‐3.02, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tiotropium 18 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐3.00, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life St George's Respiratory Questionnaire responder analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.31, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.12, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.35, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospital admission (all cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.68, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.70, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Tiotropium 18 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.37, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hospital admission (exacerbation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.66, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.46, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.67, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Tiotropium 18 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.32, 29.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality (all cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.62, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.40, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.56, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Tiotropium 18 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.69, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.69, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Tiotropium 18 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.36, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Trough forced expiratory volume in one second (FEV<sub>1</sub>) (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.06, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.04, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.06, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Tiotropium 18 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.05, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serious adverse event (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.77, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.70, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.70, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Tiotropium 18 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.50, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Tiotropium 2.5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.44, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Tiotropium 5 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.49, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Tiotropium 18 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.56, 1.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Long‐acting beta2‐agonists (LABA) plus tiotropium versus LABA alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008989.pub3/references#CD008989-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008989.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008989-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008989-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD008989-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008989\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008989\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008989\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008989\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008989\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008989.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008989.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008989.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008989.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008989.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714849338"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008989.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714849342"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008989.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d78b75ae5937d',t:'MTc0MDcxNDg0OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 